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Cover illustration: p53 is known as the “Guardian of the Genome” because it protects our DNA 
from damage and thereby prevents cancer formation. p53 mutation disrupts this protective 
capacity as illustrated by the broken shield. The plaster represents mutant p53-reactivating 
compound APR-246 that restores normal p53 function. Cancer cells have elevated antioxidants  
defense systems (pictured as jail bars) to capture oxidants. APR-246 also binds antioxidants, 
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POPULAR SCIENCE SUMMARY OF THE THESIS 
We have approximately 22,000 genes in our genome. A gene functions as a template for 
production of a specific protein, for example an enzyme or a cell surface receptor. In principle, 
one gene encodes one protein, but in many cases several versions of a protein are produced by 
one specific gene, depending on how the genetic information is decoded and how the protein 
is modified after its production. All cells in our body are descendants of a fertilized egg and 
thus they all carry the same set of genes. However, different sets of genes are active in different 
cell types, endowing cells with their unique properties and functions. Different cell types form 
the various complex organ systems in our body (Weinberg, 2007).  
All our cells have quality checks and are rigorously monitored in order for cells only to produce 
their assigned proteins. When a cell divides, its genome will be copied to the next daughter 
cells. Mistakes in this process will be identified through constant quality checks and repaired. 
However, if a mistake cannot be repaired, the cell may undergo a program called “apoptosis” 
which is a controlled form of cell suicide or cell death. This will eliminate cells with potentially 
dangerous mutations that could otherwise give rise to cancer. Thus, failure to initiate apoptosis 
to eliminate such cells can lead to tumor formation (Weinberg, 2007).  
 
Figure 1 Classical “Hallmarks of Cancer” as proposed by Hanahan & Weinberg that enable tumor growth 
and spread. “Tumor-promoting inflammation” and “Genomic instability & mutation” are enabling 
characteristics that give cancer the tools to acquire the hallmarks. Figure is modified from Hanahan & 
Weinberg, 2011. 
 
Cancer can start in more or less any cell type and organ in the body. Therefore, cancer is not 
one disease, but a collective name for more than 200 diseases depending on which organ and 
cell type the development of cancer initiates (Cancerfonden, 2018).  
There are several important differences between normal cells and cancer cells. These are the  
so called “Hallmarks of cancer” (Hanahan & Weinberg, 2000, 2011) (Figure 1). One hallmark 
of cancer is the ability to avoid cell death or apoptosis. A protein called p53 has a key role in 
this process. p53 has been dubbed “Guardian of the genome” as this protein will be activated 
when there is damage to the genome. p53 can also be activated by radiation or different types 
of drugs. Activation of p53 triggers cell death by apoptosis to eliminate incipient cancer cells. 
p53 is therefore an important protector against cancer, a so called tumor suppressor. In fact, in 
around half of all cancers the TP53 gene that codes for p53 is mutated and the normal (wild 
type) function of p53 is lost (Mello & Attardi, 2018; Soussi & Wiman, 2007), allowing cancer 
cells to avoid cell death by apoptosis and growing beyond control (Figure 2).  
Some TP53 mutations can give the p53 protein new functions which can actually stimulate 
cancer development (Brosh & Rotter, 2009; Mantovani et al, 2019). The compound that is the 
focus of this thesis, APR-246, can target mutant p53 and restore, or in other words “reactivate”, 
its normal function to trigger cancer cell suicide by apoptosis (Bykov et al, 2002b). APR-246 
is being tested in clinical trials (phase III) on patients with mutant TP53 myelodysplastic 
syndrome (MDS), a type of blood cancer. APR-246 is the clinically most advanced compound 
to target mutant p53 (Bykov et al, 2018) (Figure 2).  
APR-246 is a prodrug which means that APR-246 itself is inactive. APR-246 is spontaneously 
converted to its active product called MQ (Lambert et al., 2009) – thus MQ does all the action 
in the cell. In Paper I, we discovered that MQ is pumped out of cells by a protein called MRP1. 
We used an MRP1 inhibitor to block this pump which resulted in more MQ staying inside 
cancer cells. The additional treatment with the MRP1 inhibitor greatly increased the efficacy 
of APR-246 in cultured cancer cells. The combination treatment was highly effective in 
suppressing tumor growth in mice and it almost doubled their survival time. In Paper II, we 
 
Figure 2 Mutant p53 reactivating compound APR-246 (Eprenetapopt). The tumor suppressor p53 is 
mutated in almost half of all cancers. Mutation of p53 by substitution of one amino acid (protein building 
blocks) leads to inactivation of its normal function resulting in new tumor promoting activities. APR-246 is 
currently undergoing Phase III clinical trials, based on the hypothesis that it may reactivate p53, thereby 




identified that MQ binds specific cysteines (i.e. a type of protein building block) in the p53 
protein and that this binding differs between normal p53 and mutant p53.  
In Paper III, we discovered that APR-246 may be an efficient treatment for patients with acute 
lymphoblastic leukemia (ALL), another type of blood cancer. ALL patients are usually children 
and with today’s treatment 90% of childhood ALL patients will survive (Barncancerfonden, 
2017a). However, sometimes ALL patients relapse and become resistant to treatment. These 
relapsed ALL patients often have mutated p53 but may also produce a high amount of a protein 
called ASNS (Hof et al, 2011; Lanvers-Kaminsky, 2017). ASNS makes ALL insensitive to one 
of the standard treatments used in the clinics called asparaginase (Aslanian et al, 2001). We 
discovered that APR-246 may target the function of ASNS, thereby increasing asparaginase 
efficiency and killing of ALL cancer cells. 
Most mutations in the TP53 gene are acquired, i.e. they are not present at birth and occur before 
or during cancer development – so called somatic mutations. However, sometimes TP53 
mutation is inherited from a parent, meaning that the mutation is present in all cells of the body. 
This is a so called germline TP53 mutation. Such mutations occur in Li-Fraumeni Syndrome 
(LFS), where individuals develop cancer, even multiple cancers, with very high incidence 
during their life time (Malkin, 2011). Many of these develop tumors already during childhood 
or adolescence. Families with hereditary breast cancer may also have germline TP53 mutations 
(without being classified as LFS) (Evans et al, 2020). However, not all family members 
develop cancer and therefore it is important to understand which types of germline TP53 
mutations increase the risk for cancer and which do not. In Paper IV, we studied ten newly 
identified germline TP53 mutations found in Swedish families with LFS or hereditary breast 
cancer. We evaluated if the different TP53 gene mutations produce a p53 protein that has lost 
its normal tumor suppressive function. This is important information so that families with these 
mutations may know if they have an increased risk of developing cancer. If so, they can 
undergo preventive measures in order to decrease their cancer risk or detect cancer early.  
The first three projects are aimed at improving our understanding of mutant p53-reactivating 
compound APR-246. They suggest approaches for increasing treatment efficacy and novel 
combination strategies. The thesis has also addressed the role of mutant p53 in response to 
APR-246 and pathological properties in families with LFS or hereditary breast cancer. All in 
all, these studies provide novel preclinical understanding of the role of mutant p53 in cancer 






Tumor suppressor TP53 is the most frequently mutated gene in cancer. A majority of TP53 
mutations result in a mutant p53 that disrupts its DNA binding capabilities but may also acquire 
novel gain-of-function activities that contribute to tumor growth. The investigational drug 
APR-246 (Eprenetapopt) is the most clinically advanced compound to target mutant p53 and 
is being tested in a phase III clinical trial in mutant TP53 myelodysplastic syndrome (MDS). 
APR-246 is converted to its active product methylene quinuclidinone (MQ). MQ binds to 
cysteines in p53 promoting a folded structure and DNA binding, leading to cancer cell death. 
MQ also targets thiols or selenols in e.g. glutathione (GSH) or various enzymes. Depletion of 
glutathione and inhibition of antioxidant enzymes increase oxidative stress contributing to 
APR-246-induced cancer cell death. 
In Project I, combination treatment of APR-246 and multidrug resistance protein 1 (MRP1) 
inhibitor resulted in synergistic growth suppression in vitro in tumor cell lines, in vivo in 
esophageal cancer xenografts, and ex vivo in esophageal and colorectal cancer patient-derived 
organoids (PDO). We show that inhibition of MRP1 results in increased intracellular 14C-
content after 14C-APR-246 treatment. This was attributed to retention of GSH-conjugated MQ 
(GS-MQ). We demonstrate that GS-MQ binding is reversible and that retention of GS-MQ 
creates an intracellular MQ pool that may target numerous thiols contributing to APR-246-
induced growth suppression. In Project II we studied the spectrum of MQ-targeted cysteines 
in p53. This was enabled by first establishing a method utilizing the reducing agent NaBH4 to 
lock the MQ cysteine adducts into a stable form, overcoming reversibility. Cys182, Cys229 
and Cys277 in the p53 core domain showed most prominent MQ modification. Additional 
modification at Cys124 and Cys141 was found in mutant p53. The electrophilic properties of 
MQ enables targeting of multiple cellular thiols. In Project III we identified novel MQ targets 
using CEllular Thermal Shift Assay (CETSA). Asparaginase synthetase (ASNS) was stabilized 
upon MQ treatment and thus is a potential MQ target. In acute lymphoblastic leukemia (ALL), 
ASNS is associated with resistance to standard treatment asparaginase. Asparaginase depletes 
extracellular asparagine which renders asparagine-auxotrophic ALL cells sensitive and 
therefore ASNS expression allows ALL cell survival. We found that combination treatment of 
APR-246 and asparaginase leads to synergistic growth suppression in ALL cells and may offer 
a novel treatment strategy for ALL. Lastly, in Project IV we assessed the functional activity 
of novel germline TP53 mutations identified in a Swedish cohort of families with Li-Fraumeni 
syndrome (LFS) or hereditary breast cancer (HrBC). Assessing the pathological outcome of 
TP53 mutations is important for understanding the cancer risk of these families. 
The first three projects are aimed at improving our understanding of mutant p53-reactivating 
compound APR-246. They suggest approaches for increasing treatment efficacy and novel 
combination strategies. The thesis has also addressed the role of mutant p53 in response to 
APR-246 and pathological properties in families with LFS or HrBC. All in all, these studies 
provide novel preclinical understanding of the role of mutant p53 in cancer and response to 
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LIST OF ABBREVIATIONS 
Abbreviation Explaination 
13q14 Chromosome 13, long (q) arm, region 1, band 4 
14C-APR-246  Carbon-14 (radioactive isotope)-labelled APR-246 
17p13 Chromosome 17, short (p) arm, region 1, band 3 
3BA 3-benzoylacrylic acid  
5-FU Fluorouracil 
A Adenine (nucleobase) 
A or Ala Alanine 
Akt Protein kinase B  
ALL Acute lymphoblastic leukemia  
AML Acute myeloid leukemia  
APC Adenomatous polyposis coli  
ARE Antioxidant response elements  
ARF Alternative Reading Frame 
ARF-BP1 ARF binding protein 1 
As Arsenic 
ASNS Asparagine synthethase 
ATM Ataxia telangiectasia mutated  
ATO Arsenic trioxide 
ATP Adenosine triphosphate 
ATR ATM–Rad3-related protein  
BCL-2 B-cell lymphoma 2  
BCR B cell receptor 
BCR-ABL1 Fusion gene of BCR and ABL1 (Philadelphia chromosome) 
BH3 BCL-2 Homology (3 BH domains) 
BRCA1  Breast cancer type 1 susceptibility protein 
BSO Buthionine sulfoximide 
BTK Bruton's tyrosine kinase 
C Cytosine (nucleobase) 
C or Cys Cysteine 
c-Met Mesenchymal epithelial transition  
CAF Cancer-associated fibroblast 
CAR-T Chimeric antigen receptor T 
Cas9 CRISPR associated protein 9 
CBP CREB-binding protein  
CDK Cyclin-dependent kinases  
CETSA CEllular Thermal Shift Assay 
CHK1 Checkpoint kinase 1  
CLL Chronic lymphocytic leukemia 
CML Chronic myelomonocytic leukemia 
COP1 Constitutively photomorphogenic 1  
CRISPR Clustered regularly interspaced short palindromic repeats 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
 
 
Cys Reduced cysteine 
CySS Oxidized cysteine (Cys-Cys) 
D or Asp Asparatic acid 
DNA Deoxyribonucleic acid 
DUB Deubiquitinating enzymes  
E or Glu Glutamic acid 
e- Electron 
EGFR  Epidermal growth factor receptor 
EMA European Medicines Agency 
EMT Epithelial-mesenchymal-transition 
EPOR Erythropoietin-receptor  
FDA U.S. Food and Drug Administration 
FDXR Ferredoxin reductase 
G Guanine (nucleobase) 
G or Gly Glycine 
G6PD Glucose-6-phosphate dehydrogenase 
GADD45  Growth arrest and DNA damage-inducible protein 
GCL Glutamate cysteine ligase  
Glu Glutamate/Glutamic acid 
GOF Gain-of-function  
GPI Glucose phosphate isomerase 
GR Glutathione reductase 
Grx Glutaredoxin  
GS-MQ Glutathione-conjugated MQ 
GSH Reduced glutathione 
GSSG Oxidized glutathione 
H or His Histidine 
HAT Histone acetyl transferases  
HAUSP Herpesvirus-associated ubiquitin-specific protease 
HDAC Histone deacetylase 
HER2 Human epidermal growth factor receptor-2  
HGSOC High Grade Serous Ovarian Cancer 
HIF1 Hypoxia-inducible factor 1 
HIPK2 Homeodomain interacting protein kinase 2 
HK III Hexokinase 3 
HO-1 Heme oxygenase 1 
iASPP Inhibitory member of the ASPP family 
IDH Isocitrate dehydrogenase [NADP]  
K or Lys Lysine 
KEAP1 Kelch-ECH-associated protein 1  
KRAS GTPase KRas 
LFS Li-Fraumeni syndrome 
LMW Low molecular weight 
LOF Loss of heterozygosity  
LOH Loss-of-function 
MAPK Mitogen activate protein kinase 
MCL Mantle cell lymphoma 
MDM2 Mouse double minute 2 
MDS Myelodysplastic syndrome  
MEK Mitogen-activated extracellular signal-regulated kinase  
MHC I Major histocompatibility complex class 1 
miR-15a MicroRNA-15a 
MQ Methylene quinuclidinone  
Mre11 Meiotic recombination 11 
MRP1 Multidrug resistance protein 1  
MS-CETSA Mass spectrometry-based CETSA 
mTOR Mechanistic target of rapamycin 
mut p53 Mutated p53 
N or Asn Asparagine 
NaBH4 Sodium borohydride 
NADPH Nicotinamide adenine dinucleotide phosphate  
NK cells Natural killer cells 
NCI US National Cancer Institute  
NFkB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHL Non Hodgkin Lymphoma 
NIH National Cancer Institute  
NoLS Nucleolar localization signals 
NQO1 NAD(P)H:quinone oxireductase 
NRF2 Nuclear factor erythroid 2-related factor 2  
NSCLC Non small cell lung cancer 
ox Oxidation (loss of electrons by an atom) 
p53 Protein encoded by the gene TP53  
p53AIP1 p53-regulated apoptosis-inducing protein 1  
PARP Poly (ADP-ribose) polymerase 
PCAF p300/CBP-associated factor 
PD-1 Programmed cell death protein 1  
PD-L1  Programmed death-ligand 1 
PDO Patient-derived organoid 
PI3K Phosphatidylinositol 3-kinase  
PI3KCA PI3K catalytic subunit alpha isoform  
PIG3 p53 inducible gene 3 
Pin1 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 
PLD Pegylated Liposomal Doxorubicin Hydrochloride 
PML-RARa Promyelocytic leukemia/retinoic acid receptor alpha  
PPP Pentose phosphate pathway  
PRIMA-1 p53 reactivation and induction of massive apoptosis 
PRIMA-1Met Methylated PRIMA-1 
PSMA2 Proteasome subunit alpha type-2 
PSMC1 Proteasome 26S ATPase Subunit 1 





Q or Gln  Glutamine 
R or Arg Arginine 
R-S- or R-SH Thiol group (contains sulfur) 
R-Se- or R-SeH Selenol group (contains selenium) 
RB1 Retinoblastoma-associated protein 
RE Response elements  
red Reduction (gain of electrons by an atom) 
Redox Reduction and oxidation reactions 
S o Ser Serine 
SAH-p53 Stabilized alpha-helix of p53 
SCO2 Synthesis of cytochrome C oxidase 2 
Se Selenium 
SESN1 Sestrin 1 
siRNA Small interfering RNA 
SLC7A11 Solute carrier family 7 member 11  
T Thymine (nucleobase) 
T or Thr Threonine 
TCGA The Cancer Genome Atlas Program  
TCR T cell receptor 
TERT Telomerase reverse transcriptase  
TGF-β  Transforming growth factor beta 
TNFR1  Tumor necrosis factor receptor 1 
TNFα Tumor necrosis factor alpha 
TP53  Gene encoding p53 protein  
TP53INP1 Tumor protein p53-inducible nuclear protein 1 
TRP14 Thioredoxin-related protein 14  
Trx Thioredoxin 
TrxR1 Thioredoxin reductase 1 
U or Sec Selenocysteine 
ULBP1 UL16-binding protein 1 
V or Val Valine  
VEGF Vascular endothelial growth factor 
W or Trp Tryptophan 
WB-CETSA Western blot-based CETSA 
wt p53 Wild type p53 
Y or Tyr Tyrosine 
YY1 Ying yang 1 
ZMC-1 Zinc metallochaperone-1 








It is estimated that at least every third person in Sweden will be diagnosed with cancer during 
her/his life time. In other words, cancer is common and everyone is affected in one way or 
another. Cancer could be seen as 200 different diseases, depending on which organ and cell 
type the tumor has arisen from (Cancerfonden, 2018). Cancer cells are characterized by certain 
traits or so called “Hallmarks of Cancer” as proposed by Hanahan and Weinberg in two 
classical review articles (Hanahan & Weinberg, 2000, 2011). The Hallmarks of Cancer consists 
of capabilities acquired during the multiple steps of cancer development from initiation to 
metastatic dissemination (Figure 1 and a modified version in Figure 3). Another important 
feature of cancer and important to therapy response is redox imbalance which is described in 
 
Figure 3 Targeting Hallmarks of Cancer. The classical “Hallmarks of Cancer” in blue as proposed by 
Hanahan & Weinberg and a potential addition in green relevant for this thesis. In red is an updated version of 
mechanisms for therapeutic targeting of these hallmarks as was initially suggested by Hanahan & Weinberg. 




section 1.6 and has been added as another Hallmark of Cancer in Figure 3. These hallmarks 
illustrate the complexity of the disease, the many ways therapy resistance can occur as well as 
the uniqueness of each tumor and patient. On top of that, a tumor does not only consist of tumor 
cells but is a highly complicated landscape with many other components such as immune cells, 
fibroblasts, endothelial cells, pericytes as well as the extracellular matrix which all may play a 
role in tumor initiation, growth and progression (Dunn et al, 2004; Pietras & Ostman, 2010).  
One enabling characteristic that give cancer cells the tools to develop these capabilities is 
genomic instability that leads to random mutations (Hanahan & Weinberg, 2011). Mutations 
that inactivate tumor suppressors (genes that prevent growth or tumor formation) or activates 
oncogenes (genes that drive tumor formation) are selected in a Darwinian process that 
continues throughout the development of a tumor. Thus, cancer is also a highly dynamic 
disease and tumor heterogeneity increases with time (Dagogo-Jack & Shaw, 2018). Different 
cancer types carry different mutations that drive tumor formation and each patient will have 
their unique fingerprint of mutations. Several novel highly precise treatments that target 
specific pathways aberrant in a patient’s tumor, many of which are described in the Hallmarks 
of Cancer, have been developed in recent years (red text in Figure 3). The future of cancer 
therapy moves towards a highly personalized and complex treatment strategy which will be 
determined based on an individual patient’s genomic fingerprint containing mutations but 
importantly also its functional consequence (Letai, 2017).  
1.2 TARGETING HALLMARKS OF CANCER 
1.2.1 Resisting cell death 
Cancer is an evolutionary process driven by mutations and leading to uncontrolled cell cycle 
progression. Fortunately, if proliferation becomes aberrant, cells have innate tumor-
suppressive mechanisms that will trigger a highly regulated form of programmed cell death 
called apoptosis (Lowe et al, 2004). Thus, effective tumor suppression requires a highly 
controlled system with various abnormality sensors set in place to trigger apoptosis at the right 
moment in order to prevent uncontrolled proliferation and cancer development (Hanahan & 
Weinberg, 2011; Junttila & Evan, 2009). One example is the DNA damage response pathway, 
which upon DNA damage results in kinases (e.g. ATM, ATR, Chk1 and Chk2) that 
phosphorylate transcription factor p53. This leads to p53 stabilization which can unleash the 
highly regulated process of apoptosis (Junttila & Evan, 2009). There are several other sensors 
or signals that may trigger p53 stabilization (discussed in section1.3.1) which activate a cascade 
of chain reactions with various outcomes, including apoptosis, depending on the initial signal. 
p53 is considered the “Guardian of the Genome” as these outcomes ultimately act to preserve 
genome integrity and may for example trigger a DNA repair program. However, upon severe 
stress or oncogenic signals, p53 may be activated to induce apoptosis, and thus it is not 
unexpected that the TP53 gene is mutated in a large fraction of human tumors (see Table 1). In 
other words, there is a strong selection against a functional p53 pathway during tumor 
development (Junttila & Evan, 2009) (discussed in section 1.4). Thus, p53 plays a major role 
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in the hallmark “Resisting cell death” (Figure 3) and targeting of mutated p53 is an interesting 
strategy for novel cancer therapy (discussed in section 1.5).  
1.2.1.1 BCL-2 inhibitors 
Apoptosis serves as a natural barrier to tumor formation, as any potential unrestrained cell will 
be eliminated, and thus “Resisting cell death” is one of the cancer hallmarks (Hanahan & 
Weinberg, 2000) (Figure 3). In brief, there are two programs of apoptosis: intrinsic, via the 
mitochondria, and extrinsic, via the activation of death receptors such as Fas/CD95, TNFR and 
DF-5 and their ligands FasL, TNFα and TRAIL. The intrinsic pathway depends on a balance 
of proapoptotic Bax/Bak, located on the mitochondrial membrane, and anti-apoptotic BCL-
2/BclXL proteins that inhibit Bax/Bak activity. Both Bax/Bak and BCL-2/BclXL are positively 
or negatively regulated, respectively, by BH3-only members. When the pro-apoptotic proteins 
outweigh the anti-apoptotic proteins the mitochondrial membrane is permeabilized resulting in 
the release of pro-apoptotic proteins such as cytochrome c. This will initiate a proteolytic 
cascade of caspase cleavage which will cleave other proteins and cause an ordered cell death 
and engulfment process (Hanahan & Weinberg, 2011; Lowe et al., 2004). Apoptosis is a highly 
regulated pathway and genes involved are frequently mutated in cancer in order to defect cell 
death. Chronic lymphocytic leukemia (CLL) is the most common leukemia and almost all 
patients have overexpression of the oncogene BCL-2. This may be caused by inhibition of its 
negative regulators miR-15a and miR16-1 through 13q14 loss, or due to translocation of the 
BCL-2 gene to the immunoglobulin heavy chain locus (Cimmino et al, 2005; Pekarsky et al, 
2018). Venetoclax is the first U.S. Food and Drug Administration (FDA)-approved (in 2016) 
selective BCL-2 antagonist for the treatment of an aggressive form of CLL. Relapsed/refractory 
CLL patients or chemoresistant patients with 17p13 deletion (loss of TP53) had nearly 80% 
response rate after being treated with Venetoclax alone (Croce & Reed, 2016).  
1.2.2 Sustaining proliferative signaling and evading growth suppressors 
1.2.2.1 HER2 and PI3K inhibitors 
It is generally considered easier to therapeutically target oncogenes, as mutations result in 
hyperactive protein variants, compared to tumor suppressors which usually are inactivated or 
deleted (Soussi & Wiman, 2015). There are many success stories in targeting oncogenes and 
several inhibitors have also been approved for clinical use. One example of a routinely targeted 
oncogene is human epidermal growth factor receptor-2 (HER2) that has diverse biological 
effects e.g. signaling via phosphatidylinositol 3-kinase (PI3K) and downstream protein kinase 
B (Akt) (Alzahrani, 2019; Moasser, 2007) which regulate many pathways including 
proliferation (Ellis & Ma, 2019). HER2 is overexpressed in breast cancer (15-20%) (Loibl & 
Gianni, 2017), ovarian cancer and some other solid tumors (Moasser, 2007). For years 
trastuzumab (HER2 inhibitor) has been standard treatment of care for HER2 positive breast 
cancer patients (Loibl & Gianni, 2017). In breast cancer, PI3K pathway is the most frequently 
mutated pathway (40% in hormone receptor positive breast cancer) (Ellis & Ma, 2019) and 
PI3K catalytic subunit alpha isoform (PI3KCA) (17.8%) is second most commonly mutated 
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gene (after TP53) in a study of 12 common tumor types (Kandoth et al, 2013). Due to its 
frequent aberrant activation, large efforts are made in targeting PI3K and many inhibitors have 
reached clinical trials. Some of these have been approved, including alpelisib in breast cancer, 
as well as idelalisib, copanlisib and duvelisib for hematologic malignancies (Alzahrani, 2019; 
Ellis & Ma, 2019). PI3K’s downstream target Akt seems more difficult to target but several 
inhibitors are in clinical trials (Alzahrani, 2019). Phosphatase and tensin homologue deleted on 
chromosome 10 (PTEN) negatively regulates PI3K and is one of the most frequently mutated 
tumor suppressors, with PTEN mutations in almost 10% in 12 common tumor types or over 
60% in uterine corpus endometrial carcinoma (Kandoth et al., 2013). Since many of these 
mutations result in loss of expression (Dillon & Miller, 2014), PTEN is a challenging 
therapeutic target.  
1.2.2.2 Braf inhibitors 
Another example of an activated oncogene is the serine/threonine-protein kinase B-raf (BRAF). 
Around 40-50% of metastatic melanoma patients have BRAF mutations, specifically in residue 
V600 (Sullivan et al, 2015) resulting in a hyperactivated BRAF kinase and constitutive 
signaling through the mitogen activate protein kinase (MAPK) pathway. Both the constitutive 
active BRAF kinase and PI3K/Akt pathway contribute to the cancer hallmark of “Sustaining 
proliferative signaling” (Hanahan & Weinberg, 2011; Proietti et al, 2020) Figure 3. In 2011 
FDA (and 2012 European Medicines Agency [EMA]) approved BRAFV600 inhibitor 
vemurafenib as a monotherapy for BRAFV600 mutated melanoma patients. Vemurafenib 
rapidly suppresses melanoma growth in patients. Two more BRAFV600 inhibitors, dabrafenib 
and encorafenib, were later approved (2013 and 2018 respectively) for treating BRAFV600 
melanoma (Proietti et al., 2020). Also inhibitors targeting other components of the MAPK 
pathway have been approved such as the MEK inhibitor trametinib (Sullivan et al., 2015). 
These novel molecularly targeted therapies together with novel immunotherapies have 
revolutionized treatment of metastatic melanoma over the past decade (Sullivan et al., 2015).  
1.2.2.3 CDK4/6 inhibitors 
Besides “Sustained proliferative signaling”, cancer cells have also acquired the capability of 
evading signals that suppress growth, another hallmark (Figure 3). This hallmark is tightly 
regulated by the two tumor suppressors p53 and pRb, the retinoblastoma protein. p53 may upon 
its activation halt progression of the cell cycle, and if the damage is beyond repair, trigger 
apoptosis (Hanahan & Weinberg, 2011). pRb acts as a gatekeeper of the G1-checkpoint and a 
negative regulator of cell cycle progression by repressing gene transcription needed for cell 
cycle transition but also remodels chromatin structure. In cancer, the RB1 gene is often 
functionally inactivated by mutation or deletion (Giacinti & Giordano, 2006) while positive 
regulators of cell cycle progression are often amplified, such as cyclin D1 (2nd most amplified 
locus in cancer), and cyclin-dependent kinases (CDK) such as CDK4 or CDK6 (Otto & 
Sicinski, 2017). These aberrantly regulated cell cycle regulators are attractive targets as 
exemplified by the many CDK4/6 inhibitors in clinical trial and approval of palbociclib, 
ribociclib and abemaciclib in breast cancer (Otto & Sicinski, 2017).  
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1.2.3 Deregulating energetics 
Cancer cells have altered metabolic requirements in order to sustain their high proliferation 
rates. They rely on aerobic glycolysis, the so called “Warburg effect” (Hanahan & Weinberg, 
2011). It is not fully understood why cancer cells switch to a much less efficient pathway for 
generating adenosine 5´-triphosphate (ATP) (Hanahan & Weinberg, 2011), but one reason may 
be the need to increase availability of nutrients for building biomass e.g. amino acids, 
nucleotides and lipids, but also reductive power in form of nicotinamide adenine dinucleotide 
phosphate (NADPH) (Vander Heiden et al, 2009). NADPH is important for the antioxidant 
system as will be discussed further in section 1.6.   
1.2.3.1 Asparaginase 
One successful example of how to specifically target the altered metabolism of cancer cells is 
asparaginase which has been standard treatment of care for acute lymphoblastic leukemia 
(ALL) patients for several decades (Hoelzer et al, 2016; Lanvers-Kaminsky, 2017). 
Asparaginase depletes extracellular asparagine, and as ALL cells are asparagine auxotrophs, 
the leukemic cells are highly sensitive to this treatment. Asparaginase treatment on its own may 
induce complete remission in up to 40-60% of patients. Many tumor cells are also highly 
dependent on glutamine for the production of NADPH (DeBerardinis et al, 2007), and thus 
asparaginase’s glutaminase activity contributes to its anti-tumor activities (Emadi et al, 2014; 
Lanvers-Kaminsky, 2017; Parmentier et al, 2015). Asparaginase treatment will be further 
discussed in Project III.  
1.3 TUMOR SUPPRESSOR p53 
Inactivation of the p53 transcription factor, denoted the “Guardian of the Genome”, is the most 
common anti-apoptotic lesion in cancer (Vousden & Lu, 2002) and p53 is thus a major player 
in the hallmark of “Resisting cell death” (Figure 3). Its role as a critical brake of tumor 
development is well established (Vogelstein et al, 2000). Although discovered more than four 
decades ago p53 (Lane & Crawford, 1979; Linzer & Levine, 1979), novel and sometimes 
bewildering roles of this tumor suppressor are still revealed. p53 was originally considered an 
oncogene, in part because tumors often express high levels of p53 protein (Soussi & Wiman, 
2015) However, the findings that transfection of wild type p53 cDNA can suppress tumor cell 
growth and that the TP53 gene is frequently mutated in common types of cancer made it clear 
that p53 actually is a tumor suppressor (Baker et al, 1989; Finlay et al, 1989; Nigro et al, 1989). 
Years later, two p53-related genes, p63 (Yang et al, 1998) and p73 (Kaghad et al, 1997), with 
overlapping DNA binding domain sequences and thus shared capacity to transactivate p53-
responsive genes were identified (Bourdon, 2007b). Despite their ability to transactivate many 
of p53’s downstream targets, the family members p63 and p73 are not redundant to p53, and 
loss of either gene will cause distinct phenotypes (Bourdon, 2007b). Furthermore, all three 
family members express different protein domains, so called isoforms, that may have distinct 
functions (Bourdon, 2007b) and are abnormally expressed in cancer (Bourdon, 2007a).  
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1.3.1 Triggers for p53 stabilization 
1.3.1.1 Posttranslational modifications of p53 
At basal or normal condition p53 levels are low and in a latent, inactive form, but upon certain 
triggers or stress stimuli p53 rapidly stabilizes which will lead to an outcome depending on the 
trigger and the cellular context (Giaccia & Kastan, 1998; Lavin & Gueven, 2006). Stabilization 
of p53 is achieved by inducing a cascade of posttranslational modifications of p53 protein 
resulting in an increased protein activity as well as inducing TP53 transcription (Giaccia & 
Kastan, 1998). However, regulation of TP53 transcription mainly occurs during development 
of certain tissues (Giaccia & Kastan, 1998) while for example oncogenic stress and DNA 
damage induce p53 protein activity via posttranslational modifications (Junttila & Evan, 2009). 
Depending on the initial trigger p53 has many sites that are targeted by various enzymes for 
posttranslational modifications such as phosphorylation, acetylation, methylation, 
ubiquitination and sumoylation (Figure 4). Posttranslational modifications mainly occur in the 
N-terminal transactivation and C-terminal oligomerization domains (Lavin & Gueven, 2006; 
Xu, 2003). The N-terminus is important for interaction with its negative regulator mouse 
double minute 2 (MDM2) and its transactivation capacities. Thus, depending on the initial 
signal and the position and type of posttranslational modification the effect on p53 may result 
in for example nuclear retention, disruption of MDM2 binding, enhanced DNA binding or 
additional posttranslational modifications (Lavin & Gueven, 2006; Xu, 2003). For example, 
DNA damage-induced Ser15, Thr18 and Ser20 phosphorylation on p53 may recruit other co-
activators such as histone acetyl transferases (HAT), e.g. p300/CREB-binding protein (CBP) 
and its associated factor PCAF, leading to acetylation of the p53 C-terminal region and 
potentiation of p53 transcriptional activity (Gu & Roeder, 1997; Li et al, 2002b; Sakaguchi et 
al, 1998).  
Another posttranslational modification includes a prolyl isomerase called Pin1 (Peptidyl-prolyl 
cis-trans isomerase NIMA-interacting 1) which switches the bond between a proline and 
another amino acid from cis to trans conformation and vice versa (Mantovani et al, 2004). 
Upon DNA damage and phosphorylation of specific sites (Ser33, Thr81 and Ser315) on p53, 
Pin1 can bind and cause a confirmational change important for p53 transactivation function 
(Wulf et al, 2002; Zacchi et al, 2002; Zheng et al, 2002). Besides favoring p53 binding to target 
promotors, Pin1 is also important for p53 acetylation of specific sites and its interaction with 
oncoprotein and p53 negative regulator called iASPP (inhibitory member of the ASPP family) 
(Bergamaschi et al, 2003; Mantovani et al, 2007).  
1.3.1.2 DNA damage 
We are continuously exposed to chemicals that may be carcinogenic or mutagenic via food, 
water or in the air (Wogan et al, 2004). A clear example of a life-style exposure is smoking 
which is related to 90% of lung cancer risk in men, 70-80% in women (Walser et al, 2008) and 
other cancers (Jackson & Bartek, 2009), as tobacco carcinogens cause DNA adducts (Wogan 
et al., 2004). Besides these adducts, smoking also causes chronic inflammation, another 
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hallmark (Figure 3) that is known to promote cancer (Hanahan & Weinberg, 2011; Walser et 
al., 2008). DNA adducts were thought to occur mainly due to exposure of exogenous chemical 
carcinogens (Swenberg et al, 2011). However, DNA adducts may also occur as a result of 
several endogenous processes such as during disturbances in DNA replication (Jackson & 
Bartek, 2009) or by for example hydrolytic reactions and non-enzymatic methylations. 
Oxidative stress generated from oxidative respiration or redox cycling (discussed in section 
1.6) also contribute to DNA damage. It has been estimated that 50,000 endogenous DNA 
lesions occur daily in every cell, and this number is likely to be higher under oxidative stress 
conditions (Swenberg et al., 2011). Thus, having DNA damage sensors and repair systems set 
in place is vital in order to prevent mutations and maintain genome integrity for efficient tumor 
suppression (Jackson & Bartek, 2009).  
Cells have evolved many mechanisms to deal with DNA damage, with different types of repair 
programs depending on the type of damage (Jackson & Bartek, 2009). The DNA damage 
sensors Ataxia telangiectasia mutated (ATM) and ATM–Rad3-related protein (ATR) become 
activated upon DNA damage or replication stress and orchestrates the DNA damage response 
signaling pathway (Marechal & Zou, 2013). Upon DNA damage ATM (Banin et al, 1998) or 
ATR (Tibbetts et al, 1999) phosphorylate Ser15 on p53, which in turn leads to Ser20 
phosphorylation by Chk1 or Chk2, rendering MDM2 unable to bind p53 (Mantovani et al., 
2004). p53’s negative regulators MDM2 and MDM4 can also be phosphorylated by ATM 
(Khosravi et al, 1999) or ATR (Shinozaki et al, 2003) inhibiting MDM2-p53 interaction and 
thus prevents p53 degradation (Junttila & Evan, 2009). DNA damage leads to a severalfold 
increase of the short 5-20 minutes half-life of p53 upon ultraviolet (UV) radiation (Giaccia & 
Kastan, 1998; Maltzman & Czyzyk, 1984). UV is the most pervasive environmental DNA-
damaging agent and despite that the ozone layer absorbs most of the damaging UV spectrum, 
exposure passed through during strong sunlight can cause around 100,000 lesions per cell per 
hour (Jackson & Bartek, 2009). Besides various types of radiations, chemotherapy and 
oxidative stress can cause DNA damage and p53 activation (Christophorou et al, 2006; Jackson 
& Bartek, 2009; Junttila & Evan, 2009). The various fine-tuned effects that may occur upon 
different triggers is illustrated by the observation that both ionizing radiation (IR) and UV 
radiation lead to DNA damage but may activate different kinases to phosphorylate p53 on 
Ser15 (Ser18 in mice) (Giaccia & Kastan, 1998; Kastan et al, 1991). Double stranded DNA 
breaks activate ATM that phosphorylates p53 at various sites (Ser6, 9, 15, 20, 46 and Thr18) 
while for example phosphorylation at Thr81 occurs  upon UV and H2O2 treatment (Lavin & 
Gueven, 2006). There are also sites that may undergo dephosphorylation upon radiation 
(Waterman et al, 1998). All these posttranslational modifications induced by DNA damage are 
important triggers for p53 in its role for arresting cells to enable DNA repair programs, or if 
repair is not possible induce apoptosis.  
1.3.1.3 Oncogenic signaling 
Acute p53-activating stress such as DNA damage may be transient and result in cell cycle arrest 
and DNA repair. In other cases, severe stress may trigger p53-dependent apoptosis (Junttila & 
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Evan, 2009). Activated oncogenes (e.g. ras, myc, cyclin E) can cause double stranded DNA 
breaks due to stalling and collapse of DNA replication forks (Halazonetis et al, 2008). This 
type of DNA damage activates p53 which will induce senescence or apoptosis to eliminate 
these damaged cells. p53-induced apoptosis upon DNA damage is a highly important 
mechanism of tumor suppression. If p53 is inactivated by for example mutation, DNA damage 
may contribute to genomic instability, an enabling hallmark of cancer (Figure 3) (Hanahan & 
Weinberg, 2011), and cause progression of a pre-cancerous lesion into cancer (Gorgoulis et al, 
2005; Halazonetis et al., 2008). 
Oncogenic signaling is a persistent signal in tumor cells and may stabilize p53, not only by 
inducing DNA damage (Di Micco et al, 2006; Halazonetis et al., 2008; Junttila & Evan, 2009) 
but also by the ARF protein (Alternative Reading Frame; p19ARF in mice and p14ARF in human) 
(Christophorou et al., 2006). Mutated TP53 and loss of ARF are often found to be mutually 
exclusive in tumors (Abraham & O'Neill, 2014). The Ink4a-Arf (CDKN2A) locus codes for two 
unrelated tumor suppressors, p19ARF (ARF) and p16lnk4a (Zindy et al, 2003). p16lnk4a 
antagonizes CDKs, thereby maintaining active unphosphorylated pRb protein and blocking cell 
cycle progression. p19ARF is activated upon oncogenic signaling but not DNA damage 
(Christophorou et al., 2006) and antagonizes MDM2, resulting in either cell cycle arrest or 
apoptosis (Zindy et al., 2003). ARF binds nucleolar localization signals (NoLS) on MDM2 and 
sequesters MDM2 in the nucleoli which inhibits its interaction with p53 (Lohrum et al, 2000b; 
Weber et al, 2000; Weber et al, 1999). ARF also binds the C-terminus of MDM2 and promotes 
rapid degradation of MDM2 and thus stabilization of p53 (Zhang et al, 1998). The importance 
of two proteins encoded by the lnk4a-Arf locus is demonstrated by the fact that loss of either 
gene predisposes to tumor development (Zindy et al., 2003).  
1.3.1.4 Other triggers 
Many types of stress signals may trigger posttranslational modifications of p53 that result in its 
stabilization (Harris & Levine, 2005). These stress conditions do not need to involve DNA 
damage. One example is hypoxia, which induces HIF1a that can bind to and stabilize p53 (An 
et al, 1998). Hypoxia may also lead to p53 stabilization independently of HIFa via ATR kinase 
activation (Hammond et al, 2002). Nutrient deprivation via AMP-activated protein kinase 
(AMPK) may also induce p53 phosphorylation and thereby stabilize p53 (Lavin & Gueven, 
2006). Furthermore, p53 may be activated if ribonucleoside triphosphates or ribosomes are 
limiting for cell cycle progression. Heat and cold chock conditions leading to protein 
denaturation and aggregation can also stabilize p53 (Harris & Levine, 2005).  
1.3.1.5 Basal level p53 
Besides the various tumor suppressive functions of p53 upon stabilization of acute cellular 
stress, p53 has many physiological roles at low or basal levels of expression, including the 
regulation of fertility, cell metabolism, mitochondrial respiration, autophagy, cell adhesion and 




1.3.2 Regulation of wild type p53 
1.3.2.1 Negative regulation of p53 
A key negative regulator of p53 is MDM2 and its close homolog MDMX (MDM4) which 
directly regulate p53 levels through several mechanisms (Hock & Vousden, 2014). MDM2 
negatively regulates p53 in three ways: 1) inhibiting p53-dependent transactivation activity, 2) 
 
Figure 4 Triggers, regulation and outcomes of wild type p53 stabilization. Wild type (wt) p53 is 
stabilized by a range of different triggers and stresses at various levels. Physiological roles of p53 may not 
necessary need a trigger for p53 activation. Triggers induce p53 stabilization via posttranslational 
modifications for example phosphorylation, confirmational changes, acetylation or deubiquitination. Upon 
stabilization, p53 engages in transcriptional activation of downstream targets including its negative regulator 
MDM2 thereby forming a negative feedback loop. The various outcomes that may occur upon p53 stabilization 
are important for its role as a tumor suppressor. HAT = histone acetyl transferases, DUB = deubiquitinating 





exporting p53 from the nucleus and 3) ubiquitinating p53 for proteasomal degradation 
(Shangary & Wang, 2009). MDM2 knockout mice are embryonically lethal and will be rescued 
upon p53 inactivation (Jones et al, 1995; Montes de Oca Luna et al, 1995). MDMX mice show 
the same phenotype and are also rescued by loss of p53 (Migliorini et al, 2002; Parant et al, 
2001), and thus MDMX is just as important as MDM2 in regulating p53 (Brooks & Gu, 2006).  
As described in section 1.3.1, DNA damage induces posttranslational modifications of p53 that 
decrease p53-MDM2 binding, thereby stabilizing p53. Thus, regulation of MDM2 activity is 
critical for controlling p53 stabilization and consequently an attractive therapeutic target 
(described in section 1.5.1). MDM2 binds to hydrophobic residues at the p53 N-terminus 
(Shangary & Wang, 2009; Vassilev et al, 2004). These residues are also important for the 
transactivation activities of p53, supporting the notion that MDM2 binding can directly block 
transactivation of downstream p53 target genes (Kussie et al, 1996). MDM2 can also bind to 
the oligomerization domain on the C-terminal region which contributes to efficient MDM2 
binding as well as degradation of p53 (Kubbutat et al, 1998). Even the DNA-binding domain 
has been reported to provide a binding site for MDM2 (Shimizu et al, 2002; Wallace et al, 
2006). 
The most well-known mechanism for regulation of p53 is ubiquitination by MDM2’s E3 ligase 
activity that targets p53 for proteasomal degradation (Haupt et al, 1997; Honda et al, 1997; 
Kubbutat et al, 1997). However, MDM2 ubiquitination must not necessarily induce p53 
degradation, but depending on ubiquitination chain length it can result in different outcomes. 
Low levels of MDM2 leads to mono-ubiquitination and nuclear export of p53 while high 
MDM2 levels leads to poly-ubiquitination of p53 and nuclear degradation by the proteosome 
(Li et al, 2003). MDMX, on the other hand, lacks E3 ligase activity and cannot ubiquitinate 
p53. But like MDM2, MDMX also interacts directly with p53’s N-terminal transactivation 
domain and efficiently blocks p53 transcription activity. (Brooks & Gu, 2006; Burgess et al, 
2016). MDMX and MDM2 form heterodimers by binding each others C-termini and the 
heterodimers efficiently ubiquitinate p53 (Leslie et al, 2015). MDMX mutations that disable 
heterodimerization with MDM2 are also embryonically lethal, and so its heterodimer formation 
seems essential for p53 degradation, at least during embryonic development (Kruse & Gu, 
2009; Leslie et al., 2015). 
Other mechanisms by which MDM2 blocks p53 function include blocking co-activators such 
as p300 (Kobet et al, 2000) and recruiting repressors such as histone deacetylases (Ito et al, 
2002) which both results in inhibition of p53s transcriptional activity. MDM2 binding has also 
been reported to induce a conformational shift in p53, making it unable to bind DNA (Sasaki 
et al, 2007). Lastly, it should be mentioned that other E3-ligases can target p53 for proteasomal 
degradation including constitutively photomorphogenic 1 (COP1) (Dornan et al, 2004), Pirh2 
(Leng et al, 2003) and ARF binding protein 1(Arf-BP1) (Chen et al, 2005). 
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1.3.2.2 Regulation of MDM2 
Under normal conditions the p53 network is “off” and only activated upon stress or damage 
(Vogelstein et al., 2000). p53 activation result in high p53 levels and therefore a rapid negative 
regulatory mechanism is essential to terminate the p53 response when the problem is resolved. 
This function is carried out by MDM2, which consequently is upregulated as it is an important 
downstream target of p53. Additionally, p53 also upregulates E3 ligases PirH2 (Leng et al., 
2003) and Cop1 (Dornan et al., 2004), as well as the phosphatase Wip1 (Lu et al, 2007) which 
dephosphorylates and stabilizes MDM2. Together with MDM2 they form a complex feedback 
loop, regulating wild type p53 and ensuring high p53 turnover allowing cells to return to an 
unstressed state once the p53 induction is removed (Hock & Vousden, 2014). Other positive 
regulators of MDM2 include transcription factor ying yang 1 (YY1) which works as a cofactor 
to promote MDM2 interaction with p53 while also being compromised by ARF1 (Sui et al, 
2004). Akt has been reported to phosphorylate MDM2 at Ser166 resulting in the translocation 
of MDM2 to the nucleus  where it can exert its negative regulation on p53 (Gottlieb et al, 2002; 
Mayo & Donner, 2001; Ogawara et al, 2002; Zhou et al, 2001).  
The regulation of p53 by MDM2 is complicated and as mentioned previously many factors 
may affect stability of p53 or MDM2 and their interaction. Like p53, MDM2 is also regulated 
by phosphorylation and acetylation of various sites. For example, phosphorylation of Ser395 
by ATM inhibits MDM2 function, while phosphorylation of other sites (Ser166 and Ser186) 
increases its E3 ligase activity . Other proteins may bind and inhibit MDM2 function, for 
example ribosomal proteins L5, L11 and L23, thereby regulating p53 activation during 
ribosomal stress (Kruse & Gu, 2009). Furthermore, MDM2 is an unstable protein as it 
ubiquitinates itself or is ubiquitinated by other E3 ligases (Fang et al, 2000; Kruse & Gu, 2009). 
For example, upon DNA damage MDM2 is autoubiquitinated resulting in increased p53 
activity. Thus, controlling MDM2 degradation is another mean in regulating p53 activity 
(Brooks & Gu, 2006; Stommel & Wahl, 2004). The discovery of deubiquitinating enzymes 
(DUBs) challenged the existing concept of the monodirectional destiny of a ubiquitinated 
substrate and showed that ubiquitination is a highly dynamic process (Brooks & Gu, 2006). A 
DUB called herpesvirus-associated ubiquitin-specific protease (HAUSP) can remove the 
ubiquitination on p53 (Li et al, 2002a) but also on MDM2 (Cummins & Vogelstein, 2004), and 
thereby controlling p53 stability. HAUSP’s capacity to remove ubiquitination on p53 while at 
the same regulating autoubiquitination of MDM2 triggered by DNA damage works as a 
“switch” that allows a quick p53 stabilization in response to stress (Brooks & Gu, 2006).  
1.3.3 Downstream targets and outcomes of p53 activation 
p53 is a transcription factor and is biologically active as a homotetramer that binds DNA 
(Joerger & Fersht, 2010; Raj & Attardi, 2017). p53 binds to a DNA binding motif or response 
elements (RE) with the consensus sequence 5'-Pu-Pu-Pu-C-A/T-A/T-G-Py-Py-Py-3' (where Pu 
is purine and Py is pyrimidine), located in the promotor of its target genes and thereby activates 
transcription of these specific genes (el-Deiry et al, 1992; Farmer et al, 1992; Funk et al, 1992). 
More than one hundred genes are transcriptionally activated by p53 (Andrysik et al, 2017; 
 
12 
Donehower et al, 2019) and the list continues to grow (Lane & Levine, 2010). p53 also 
mediates transcription-independent activities by directly interacting with other proteins or 
enzymes (Kruiswijk et al, 2015). 
The pro-apoptotic genes of Bax, Puma and Noxa have p53 binding sites and induce apoptosis 
upon transactivation by p53 (Shaw et al, 1992). Another important role is p53’s ability to inhibit 
cell proliferation and growth (Vousden & Prives, 2009). Induction of p21 (as well as GADD45 
[Growth Arrest And DNA Damage-Inducible Protein] and 14-3-3 sigma) (el-Deiry, 1998; el-
Deiry et al., 1992) results in G1-arrest and is very sensitive as already low levels of p53 will 
induce p21. This allows cells to survive safely once the stress is removed, demonstrating that 
p53 activation must not necessarily trigger cell death. p21 induction can also lead to senescence 
(Brown et al, 1997), an irreversible cell cycle arrest, which prevents malignant progressions 
and in this way most likely holds back many abundant precancerous lesions that we all carry 
(Vousden & Prives, 2009). Although cell death and cell cycle arrest seem to be the major roles 
of p53 there are also many other cellular outcomes of p53 stabilization. For example, p53 
mediates antiangiogenic activities (Teodoro et al, 2007) and antioxidant activities by reducing 
intracellular reactive oxygen species (Liu et al, 2008; Sablina et al, 2005) (described in section 
1.3.3.1). Additionally, p53 engages factors involved in DNA repair such as inducing RAD51-
dependent homologous repair as well as repressing the aberrant processing of replication forks 
if lesions are not repaired (Gatz & Wiesmuller, 2006). During starvation p53 can regulate 
autophagy by inducing lysosomal proteins DRAM or through the negative regulator mTOR 
(Crighton et al, 2006; Mathew et al, 2007). p53 may also regulate other tumor suppressors, for 
example PTEN (Stambolic et al, 2001) which negatively regulates the PI3K/Akt survival 
pathway (Song et al, 2012). Thus, p53 activation may result in a whole range of various 
outcomes, including proliferation, differentiation, stem cell reprogramming, metabolism and 
migration (Kruiswijk et al., 2015).  
In many cases it is not straight forward if p53 activation will lead to positive or negative 
regulation of outcomes as reflected in its dual roles in cell fate where it can induce apoptosis 
but also has the capability to promote cell survival (Kruiswijk et al., 2015). Likewise, p53 
activity may both increase and decrease oxidative stress or both inhibit and induce autophagy. 
The various activities of p53 are part of its tumor suppressive function. Thus, perturbation of 
p53 may provide tumors with survival advantages (Kruiswijk et al., 2015). But how does p53 
decide on the outcome of its activation? It has been suggested that p53’s activities depend on 
the amount of stress, in that basal or low stress leads to roles in mediating homeostasis while 
at irreparable damage p53-activated outcomes will eliminate the damaged cell (Kruiswijk et 
al., 2015; Li et al, 2011b). Although hundreds of genes are regulated by p53, a conserved core 
program of around 100 genes is activated, independently of cell type of cell response, and these 
genes cooperate to promote tumor suppression (Andrysik et al., 2017).  
1.3.3.1 Oxidative stress 
As mentioned, wild type p53 can both increase and decrease oxidative stress while p53 itself 
is affected by redox homeostasis (Eriksson et al, 2019; Kruiswijk et al., 2015) (Figure 5). 
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Redox regulation is introduced in section 1.6. Due to the important roles of the cysteines located 
in the DNA binding core domain (discussed in section 1.5.2.5), p53 is highly redox sensitive 
and dependent on reduction by antioxidants systems e.g. TrxR-Trx (Thioredoxin [Trx] 
reductase) and glutathione (GSH) (Eriksson et al., 2019). Additionally, the master antioxidant 
regulator Nuclear factor erythroid 2-related factor 2 (NRF2) can regulate p53 activity by 
inducing MDM2 transcription (Todoric et al, 2017; You et al, 2011). Many of the p53 target 
genes with antioxidant capacities seem to be sensitive to low levels of p53, while p53 targets 
that display prooxidant and apoptotic capabilities are activated upon higher p53 levels (Polyak 
et al, 1997; Sablina et al., 2005; Wu et al, 2017). Examples of targets with antioxidant 
capacities and part of the mentioned conserved core program (Andrysik et al., 2017) include: 
p21 (by competing with NRF2 antagonist Keap1 for NRF2 binding (Chen et al, 2009), TIGAR 
(by promoting NADPH-generating pentose phosphate pathway [PPP] (Lee et al, 2014)) and 
Sestrins 1/2 (by activating NRF2(Bae et al, 2013)). Several of the pro-apoptotic genes in the 
conserved core program (Andrysik et al., 2017) have mitochondrial functions and are 
associated with mitochondrial leakage of oxidant species e.g. Bax, Bak, Puma and Noxa 
(Eriksson et al., 2019). p53 protein may also directly interact with and inhibit PPP-rate-limiting 
G6PD (glucose-6-phosphate dehydrogenase), thereby resulting in decreased NAPDH 
production and thus reductive power(Jiang et al, 2011). 
Ferroptosis is a type of a cell death that is characterized by iron and lipid hydroperoxide 
accumulation and is considered important for p53 tumor suppression (Jiang et al, 2015; 
Maiorino et al, 2018; Stockwell et al, 2017; Tarangelo et al, 2018). Sensitivity to ferroptosis is 
associated with availability of GSH, cysteine and NADPH as well as iron homeostasis and fatty 
acid metabolism (Stockwell et al., 2017). Both NRF2 and p53 transactivation may prevent 
ferroptosis, although p53 may also stimulate ferroptosis for example by its negative regulation 
of cystine/glutamate antiporter SLC7A11 (Jiang et al., 2015; Maiorino et al., 2018; Tarangelo 
et al., 2018). p53 and its relationship to redox homeostasis is complicated. Although the 
negative regulation of SLC7A11 results in a decreased import of glutathione building blocks, 
many other p53 target genes act to increase GSH production such as TIGAR (Lee et al., 2014), 
GLS2 (Hu et al, 2010; Suzuki et al, 2010), Sestrins ½ (Bae et al., 2013) and p21-dependent 
NRF2 activation (Chen et al., 2009). Furthermore, the observed increase in oxygen species and 
DNA oxidation upon p53 downregulation is a reflection of the antioxidant capacities of p53 
(Sablina et al., 2005). In this context it is also noteworthy that the tumor incidence of p53 null 
mice can be lowered upon dietary supplementation of N-acetylcysteine (NAC [which can be 




1.4 MUTANT p53 
Since many processes regulated by wild type p53 are integrated in its tumor suppressive 
activity, perturbation of some of these processes by TP53 mutation provides tumors with 
survival advantages (Kruiswijk et al., 2015). Due to a large fraction of tumors harboring TP53 
mutations resulting in high expression of a mutant form of the protein (Soussi & Wiman, 2015), 
there is both a clinical need and a high interest in targeting mutant p53. The focus of this thesis, 
is the compound APR-246 which targets mutant p53, increases oxidative stress and induces 
cancer cell death (Bykov et al., 2002b; Lambert et al., 2009). APR-246 will be discussed in 
detail in section 1.5.3.  
1.4.1 Mutations in TP53 gene 
Despite intensive efforts to understand the various roles of p53, many questions are still 
unanswered and so p53 remains a truly dynamic and exciting field to unwind (Mello & Attardi, 
2018). TP53 is the most frequently mutated gene in cancer with a mutation frequency in at least 
42% of the cases in 12 common tumor types (Kandoth et al., 2013). As shown in Table 1, 
mutation frequency varies depending on cancer type, for example from rare cases (2.2%) in 
kidney renal clear cell carcinoma to almost all cases (95%) in high-grade serous ovarian cancer. 
 
Figure 5 Regulation of redox balance by wild type p53 and vice versa. Wild type p53 function is dependent 
on a reduced environment while its function is compromised in oxidative conditions. p53 may induce targets 
that have antioxidant capacities but can also result in activities that generate oxidative stress. p53 may induce 
activities that lead to NRF2 activation while NRF2 can negatively regulate p53 by inducing MDM2. Red and 




Advanced stages of cancer are often associated with a higher frequency of mutated TP53, for 
example metastatic or advanced prostate cancer (29% [in the MSK-IMPACT cohort]) which 
has a 4-fold higher frequency of mutated TP53 compared to untreated primary prostate cancer 
(7% [in the TCGA dataset]) (Zehir et al, 2017). Also, acute lymphoblastic leukemia (ALL) 
rarely (5%) has TP53 mutations while such mutations are more often (10-30%) found in 
relapsed patients (Blau et al, 1997; Comeaux & Mullighan, 2017; Diccianni et al, 1994; Gump 
et al, 2001; Ma et al, 2015; van Leeuwen, 2020). TP53 mutation status and its association with 
prognosis is debated, as TP53 mutation has been associated with poor survival, but there are 
also studies indicating no such association (Donehower et al., 2019; Robles & Harris, 2010; 
Roth, 1999). Thus, the impact of TP53 mutation may depend on multiple factors, e.g. cancer 
type and clinical stage. Moreover, mutant p53 associated RNA expression signatures may be a 
more valuable prognostic tools than TP53 status alone (Donehower et al., 2019). Further 
highlighting the important role of p53 as a tumor suppressor is the observation that tumors that 
do not carry TP53 mutation often have mutation in other components of the p53 pathway, for 
example mutations leading to increased expression of p53’s negative regulator MDM2 (Bond 
et al, 2004). p53 may also be inactivated by the human papilloma virus (HPV) protein E6 that 
target p53 for degradation (Leroy et al, 2017). This is clinically relevant in cervical cancer 
which may explain why cervical cancer rarely (5%) has TP53 mutations (Olivier et al, 2010). 
As tumor suppressors prevent cancer development, mutations in tumor suppressor genes are 
usually nonsense or out-of-frame mutations resulting in loss of protein expression as commonly 
seen in the adenomatous polyposis coli (APC) or retinoblastoma 1 (RB1) genes (Soussi & 
Wiman, 2015). Oncogenes, on the other hand, are almost exclusively altered by missense 
mutations of specific residues leading to constitutive activation. This applies to for example 
BRAF, KRAS, and PIK3CA (Vogelstein et al, 2013). However, the majority of the mutations 
in TP53 are missense point mutations in the DNA binding domain (80%), that results in 
expression of mutant p53 protein that fails to bind DNA (Soussi & Wiman, 2015).  
 
Tumor type (TCGA study) Frequency of mutation in TP53 (%) 
Bladder urothelial carcinoma (BLCA) 50.0 
Breast adenocarcinoma (BRCA) 32.9 
Colon and rectal carcinoma (COAD/READ) 58.6 
Glioblastoma multiforme (GBM) 28.3 
Head and neck squamous cell carcinoma (HNSC) 69.8 
Kidney renal clear cell carcinoma (KIRC) 2.2 
Acute myeloid leukemia (LAML) 7.5 
Lung adenocarcinoma (LUAD) 51.8 
Lung squamous cell carcinoma (LUSC) 79.3 
Ovarian serous carcinoma (OV) 94.6 
Uterine corpus endometrial carcinoma (UCEC) 27.8 
Pan-Cancer 42.0 
Table 1 Percentage of mutated TP53 in 3281 tumors across twelve individual tumor types and Pan-Cancer 
according to Kandoth, et al 2013 based on data from The Cancer Genome Atlas Program (TCGA) by the 




1.4.1.1 Mutation spectrum 
When a novel cancer gene is discovered, a unique three-phase pattern is observed as described 
by Soussi and colleagues (Leroy et al., 2017). These phases are the discovery, validation and 
the clinical relevance of the gene, and for several genes these phases can be rapid. BRAF, for 
example was first described in 2002 and is now a well established oncogene and known to 
carry one specific mutation V600E in melanoma and many other cancer types. To put this in 
perspective, since the discovery of TP53 more than 40 years ago, 60,000 variants have been 
reported in the TP53 variant database. Around 1500 different missense TP53 variants have 
been described, most of which (85%) were reported early in the discovery phase. This is a 
reflection of the increased use of NGS which has led to the discovery of rare novel germline 
TP53 variants with unknown significance. It raises the question concerning the pathogenicity 
of the many novel and rare variants reported (Leroy et al., 2017) and therefore functional 
characterization of reported variants is important as described in Project IV. 
In cancer, the majority of TP53 mutations are missense mutations that give rise to single amino 
acid substitutions in the p53 protein (Vousden & Lu, 2002). Most of the TP53 mutations occur 
in the central conserved DNA-binding domain (around 80%) (Donehower et al., 2019; Muller 
& Vousden, 2013; Sabapathy & Lane, 2018). Also frameshifts (deletions and insertions) and 
nonsense mutations may occur (Sabapathy & Lane, 2018). Ten so called “hot spot” residues 
account for around half of all TP53 mutations (Lane, 2019), six of these represent 28% of all 
mutations (Vousden & Lu, 2002) and include R175, G245, R248, R249, R273 and R282 
(Bullock & Fersht, 2001; Freed-Pastor & Prives, 2012; Vousden & Lu, 2002). Mutations in 
p53 have been divided into two categories; structural mutants (for example R175H and R249S) 
that reduces the stability of the folded protein, and DNA-contacts mutants (for example R248Q 
and R273H) that affect residues that are essential for DNA binding (Muller & Vousden, 2013; 
Sabapathy & Lane, 2018). Since missense mutant p53 is unable to transactivate its own 
feedback regulator MDM2 many tumors express high levels of mutant p53 (Donehower et al., 
2019). For this reason, high expression of p53 has often been used as a surrogate marker to 
indicate mutant p53 (Kobel et al, 2016; Robles & Harris, 2010). Often TP53 mutation occurs 
in one of the two alleles (Sabapathy & Lane, 2018). In almost all (>91%) of TP53 mutant 
tumors, the second wild type p53 allele is lost by mutation, chromosomal (17p) deletion, or 
copy-neutral loss of heterozygosity (LOH) (Donehower et al., 2019).  
1.4.1.2 Germline TP53 mutations 
Germline TP53 mutations are found in highly cancer-prone Li-Fraumeni syndrome (LFS) (Li 
& Fraumeni, 1969) and also in families with hereditary breast cancer (Leroy et al, 2014). p53’s 
important tumor suppressor role becomes evident in LFS patients where 75% of the patients 
carry germline p53 mutations (Guha & Malkin, 2017). LFS is a complex hereditary cancer 
predisposition disorder associated with early-onset cancer in various organs (Malkin et al, 
2016). Tumors that typically occur in LFS are soft-tissue sarcoma, osteosarcoma, 
adrenocortical carcinomas, central nervous system tumors and early onset (< 31 years of age) 
breast cancer in women (Evans et al., 2020). Early onset breast cancer may also occur without 
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family history of cancer, which is attributed to  de novo TP53 variants. Germline carriers of 
TP53 mutation have a lifetime risk of developing cancer with 75% for male and 100% for 
females (Malkin et al., 2016). The most common germline TP53 mutations are the same as the 
somatic TP53 mutations found in tumors i.e. hot spot mutations at codons 175, 245, 248, 273 
and 282 (Malkin, 2011). Due to the early onset of cancer, it is suggested that other genetic 
modifiers also have roles in LFS, for example various polymorphism in the p53 network. One 
such polymorphism exists in exon four in TP53, which causes an increased affinity to MDM2 
resulting in increased p53 degradation and earlier onset of tumor formation (Bougeard et al, 
2006). Another polymorphism with similar results is located in the MDM2 promoter and lead 
to increased affinity of the Sp1 transcription factor, elevated levels of MDM2 expression and 
as a consequence enhanced degradation of p53 (Bond et al., 2004). Due to their high lifetime 
risk of developing cancer, symptom-free members of LFS families undergo periodic 
surveillance. However due to the large phenotypic heterogeneity, disease management of these 
individuals is difficult (Malkin et al., 2016). There are limited preventive options available for 
LFS patients, except prophylactic mastectomy for women to reduce the risk of developing 
breast cancer (Guha & Malkin, 2017). Unfortunately, it is nearly impossible to predict age of 
onset, likelihood and cancer type or prevent cancer in LFS (Malkin et al., 2016). 
1.4.2 Mutation outcome 
1.4.2.1 Loss-of-function and gain-of-function 
The finding that missense mutant p53 proteins in general are unable to transactivate target 
genes and that they also may have oncogenic activities that are advantageous for tumors has 
led to the notion that tumors may be addicted to mutant p53 (Leroy et al., 2017). This suggests 
a strong selection for maintained expression of mutant p53 proteins that have a positive role 
for tumor development either by a loss-of-function (LOF) or gain-of-function (GOF) 
(Mantovani et al., 2019). The observation that tumors with missense TP53 mutations have 
higher oncogenic potential than TP53 null tumors may be explained by the GOF activity of 
missense mutants (Brosh & Rotter, 2009; Dittmer et al, 1993; Olive et al, 2004). Mutant p53 
may also exert dominant negative effects that lead to LOF or impairment of wild type p53 
activity (Boettcher et al, 2019; de Vries et al, 2002; Hegi et al, 2000; Srivastava et al, 1993). 
This has recently been thoroughly demonstrated in acute myeloid leukemia (AML) by 
CRISPR/Cas9 of common missense TP53 mutations (Boettcher et al., 2019). Functional DNA 
binding and transcriptional analyses revealed that the various missense p53 mutants did not 
lead to GOF, but rather LOF by dominant negative effects. Neither did AML patients harboring 
missense TP53 mutations have a more aggressive disease or difference in survival compared 
to AML patients with truncating mutations. As wild type p53 functions as a tetramer (Joerger 
& Fersht, 2010; Raj & Attardi, 2017), a dominant negative effect may occur by 
heterodimerization of mutant p53 with the wild type protein leading to a mixed dimer that is 
transcriptionally deficient (Milner & Medcalf, 1991; Shaulian et al, 1992). Furthermore, all of 
the subunits in this mixed tetramer are positive for mutation-confirmation specific antibody 
PAb240 while negative for wild type-confirmation specific antibody PAb1620 (Milner & 
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Medcalf, 1991). Due to the many important roles of p53 as the Guardian of the Genome 
(section 1.3), depriving cells of its tumor suppressive functions provides an advantage for 
cancer development (Mantovani et al., 2019). Many studies have convincingly shown both 
LOF and GOF activities of mutant p53 and it is possible that the outcome of TP53 mutation is 
context and cancer type dependent, where for instance LOF may be driving progression of 
myeloid malignancies and GOF drive epithelial malignancies in promoting invasion and 
metastasis (Boettcher et al., 2019; Lane, 2019).  
1.4.2.2 Interaction with other family members, p63 and p73 
The molecular mechanisms by which mutant p53 may exert GOF effects can be divided into 
alteration of the DNA-binding ability, enhancement or repression transcription factors, as well 
as interaction with proteins to change their functions (Muller & Vousden, 2013). Most of the 
mutations in TP53 occur in the DNA-binding domain and disrupt DNA binding. Mutant p53 
may retain some DNA-binding capacity and show promiscuous transactivation of genes that 
allows it to function as an oncogenic transcription factor, while the usual wild type p53 
response is impaired. Mutant p53 can also interact with other transcription factors to either 
enhance or repress them, one of the best examples of this being the interaction with its family 
members p63 and p73. p63 and p73 encode numerous different isoforms that to some extent 
mimic wild type p53 by activating some targets genes shared by wild type p53. Although they 
also have their own distinct biological roles, mutant p53 can engage in interaction with some 
of these isoforms to repress or enhance their function (Oren & Rotter, 2010). Mutant p53 exert 
dominant negative effects on p63 and p73 by preventing their binding to DNA but also tethers 
p63 to DNA sites not normally bound by p63 (Muller & Vousden, 2013; Murphy et al, 2000). 
Inactivation of p63/p73 seems to play a pivotal role in the GOF activity by p53 as ablation of 
p63/p73 often mimics the effects of mutant p53 while overexpression of p63/p73 can 
counteract mutant p53 activity (Oren & Rotter, 2010). For example, co-expression of mutant 
p53 (R175H) and p73a results in decreased transcriptional activity of pro-apoptotic Bax 
(1.2.1.1) and thus reduced p73-mediated apoptosis (Murphy et al., 2000). Besides interacting 
with transcription factors, mutant p53 can also interact with other proteins and modulate their 
function (Muller & Vousden, 2013), for example master antioxidant regulator NRF2 (Lisek et 
al., 2018; Liu et al., 2017; Walerych et al., 2016) (section 1.4.2.4) or Mre11, an important 
factor of homologous recombination-mediated DNA repair (Song et al, 2007) (section 1.4.2.3).  
1.4.2.3 Hallmarks of cancer 
Considering the accumulating and intense p53 research literature for the past four decades and 
the many different variants of mutant p53 that exist, mutant p53 seems to contribute to most or 
even all of the Hallmarks of cancer in one way or another (Freed-Pastor & Prives, 2012; 
Solomon et al, 2011) as illustrated in Figure 6. As mentioned, these contributions may be 
attributed to LOF and/or GOF activities of mutant p53. Eliminating wild type p53 tumor 
suppression contributes to both evading growth suppression and resisting apoptosis as p53 is a 
major regulator of these pathways (Solomon et al., 2011). Mutant p53 fails to induce p21 and 
thus p21 cannot inhibit cyclin-dependent kinases resulting in evasion of growth suppression 
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(Elbendary et al, 1996). TP53 mutation leads to loss of wild type p53-mediated apoptosis, but 
mutant p53 also protects cells from other apoptosis inducers. Mutant p53 increases induction 
of the NFkB pathway in response to TNFα, while loss of mutant p53 results in sensitization to 
TNFα-induced apoptosis (Weisz et al, 2007). TNFα is a ligand of death receptor TNFR1 
(section 1.2.1.1) and thus induces extrinsic apoptosis (Weinberg, 2007) but can also activate 
the NFkB pathway (Weisz et al., 2007). The transcription factor NFkB is often implicated in 
cancer, as it can both inhibit apoptosis and support cell proliferation (Karin, 2006). As 
constitutive activation of NFkB promotes tumor development by chronic inflammation, and 
due to the fact that wild type p53 and NFkB normally antagonize each other, activation of the 
NFkB pathway by mutant p53 contributes to several Hallmark of cancer (Gudkov & 
Komarova, 2016; Solomon et al., 2011; Weisz et al., 2007).  
Wild type p53 is dubbed Guardian of the Genome due to its ability trigger to growth arrest and 
induce DNA repair upon DNA damage (Solomon et al., 2011). In the presence of mutant p53 
many normal responses are lost. For example, genotoxic agents that normally trigger growth 
suppression or apoptosis through wild type p53 stabilization will no longer induce these 
responses. Mice carrying TP53 R248W mutations were reported to have interchromsomal 
translocation resulting in genomic instability which was not observed in TP53 null mice (Song 
et al., 2007). The interaction of mutant p53 with the nuclease Mre11 (Meiotic Recombination 
11), was shown to hamper DNA repair by homologous recombination, resulting in genomic 
instability. Mutant p53 therefore prevented the recruitment of the Mre11-Rad50-NBS1 (MRN) 
complex and DNA double-stranded breaks, consequently leading to failed ATM recruitment 
(Song et al., 2007). Moreover, DNA damage induces mutant p53 phosphorylation on Ser15 via 
ATM, which results in mutant p53 accumulation (Frum et al, 2016). As wild type p53 directly 
interacts with RAD51, BRCA1 and BRCA2, factors important for repair of double stranded 
DNA breaks, mutation or loss of wild type TP53 results in inappropriate chromosomal 
rearrangements and further genomic instability (Murphy et al., 2000). This allows cells with 
mutant p53 to accumulate more DNA damage, resulting in increased genomic instability and 
emergence of cells that drive tumor progression (Blagih et al, 2020; Sabapathy & Lane, 2018). 
Indeed, an analysis of >10,000 tumors from the TCGA dataset showed that TP53 mutation is 
associated with enhanced chromosomal instability, including deletion of tumor suppressor 
genes and amplification of oncogenes (Donehower et al., 2019). Telomeres protect 
chromosome ends and are shortened during cell propagation to prevent immortality (Hanahan 
& Weinberg, 2011). Importantly, telomere dysfunction leads to DNA damage signals that 
activate wild type p53, a tumor suppressive function that is lost upon TP53 mutation (Roake & 
Artandi, 2017). Telomerases can counteract telomere erosion by extending telomeric DNA and 
enables unlimited replication (Hanahan & Weinberg, 2011). One study has shown that p53 





Furthermore, mutant p53 may also support the Hallmark “Avoid Immune Destruction” as wild 
type p53 regulates antigen presentation pathways which are important for immune recognition 
(Blagih et al., 2020). For example, wild type p53 can promote endogenous antigen presentation 
by increased surface MHC class I-peptide complexes and peptide loading, which are both 
functions that may be lost in p53 mutant and null cells (Wang et al, 2013; Zhu et al, 1999). 
Since recognition of natural killer (NK) cells and T cells may be modulated by wild type p53, 
perturbation of wild type p53 function may lead to immune escape (Blagih et al., 2020). Wild 
type p53 may regulate expression of UL16-binding protein 1 (ULBP1) and ULBP2 recognized 
 
Figure 6 Mutant p53 in cancer. In tumor cells that carry one wild type and one mutant TP53 allele, mutant 
(mut) p53 may exert a dominant negative effect ( ) on the co-expressed wild type (wt) p53, resulting in 
inhibition of wt p53 function. Mutant p53 may also, at least in some cellular contexts, have gain-of-function 
(GOF) activities that favor tumor progression. Such activities may include illegitimate transactivation of 
transcription and promiscuous binding to cellular proteins. Genes and proteins whose transcription and/or 
function are inhibited by p53 are indicated in red , and genes and proteins whose transcription and/or 
function are stimulated by mutant p53 are indicated in green . Novel binding partners for mutant p53 are 




by NK cells (Li et al, 2011a; Textor et al, 2011), another regulation lost upon mutation. Cancer 
cells often overexpress PD-L1 which is an inhibitor signals for T cells, and loss of p53 function 
is correlated to increased PD-L1 expression (Biton et al, 2018; Blagih et al., 2020; Cortez et 
al, 2016). 
Many studies have provided evidence that mutant p53 can drive and enhance invasion and 
motility by increasing signaling through the cytokine TGF-β (Transforming growth factor beta) 
(Adorno et al, 2009), receptor EGFR (Epidermal growth factor receptor) (Sauer et al, 2010) or 
the receptor tyrosine kinase MET (Grugan et al, 2013; Muller et al, 2013) that are often 
associated with increased metastatic capacity. Additionally, by interacting with the p63 isoform 
TAp63, which does not interact with wild type p53, mutant p53 can regulate a pro-invasive 
transcription factor program (Muller & Vousden, 2014). Supporting this notion, a study using 
a mouse model of pancreatic cancer with mutant p53 showed that loss of TAp63 resulted in 
less potent induction of metastasis (Tan et al, 2014). This also supports the idea that the p63 
and p73 family plays a pivotal role in mutant p53 GOF. As wild type p53 regulates a wide array 
of pathways to counteract metastasis, for example by preventing EMT (epithelial-
mesenchymal-transition) (Muller et al, 2011), mutant p53 can promote invasion and metastasis 
in many more ways than mentioned here.  
As wild type p53 participates in almost every facet of cell behavior (Kruiswijk et al., 2015), 
the loss of its function by mutations will likely lead to the perturbation of many of these 
pathways. Furthermore, the presence of high level mutant p53 gives cancer cells the capacity 
to withstand not only DNA damage signals but also other types of stresses such as oxidative 
and proteotoxic stress, nutrient fluctuations, physical constraints and anti-tumor immune 
responses (Mantovani et al., 2019).  
1.4.2.4 Oxidative stress 
Wild type p53 regulates an ocean of processes including metabolic activities and redox 
homeostasis that both contribute in antioxidant and prooxidant responses (Kruiswijk et al., 
2015). Since mutant p53 may exert dominant negative effects on co-expressed wild type p53, 
it presumably disrupts wild type p53-mediated regulation in redox homeostasis in this setting 
(Boettcher et al., 2019; de Vries et al., 2002). The relationship between mutant p53 and redox 
homeostasis is complicated (Eriksson et al., 2019). Mutant p53 also been shown to interact 
with the master antioxidant regulator NRF2 (Walerych et al., 2016) (Figure 7).NRF2 is further 
described in section 1.6. In brief, NRF2 is a transcription factor that transactivates antioxidant 
response element (ARE) genes upon oxidative stress (Rojo de la Vega et al, 2018). However, 
its interaction with mutant p53 perturbs this regulation and some ARE genes are activated 
(TrxR1, Trx) while others are repressed (HO-1, NQO1, SLC7A11) (Lisek et al., 2018; Liu et 
al., 2017). Mutant p53 is associated with upregulation of glucose transporters and changes in 
metabolism may also affect redox homeostasis (Eriksson et al., 2019; Gomes et al, 2018). 
Furthermore, several p53 mutants are found to induce HIF a/VEGF signaling (Khromova et 
al, 2009). Since VEGF can activate NRF2, angiogenesis may also affect redox regulation 




1.5 THERAPEUTIC TARGETING OF P53  
1.5.1 Reactivating wild type p53 
1.5.1.1 p53-MDM2 interaction 
In cancers harboring wild type p53, radiation and traditional chemotherapy will induce DNA 
damage and subsequent p53 accumulation due to posttranslational modifications of p53 
(Shangary & Wang, 2009). Nonetheless, great efforts have been made design strategies to 
induce a p53 response by directly and specifically targeting the interaction of p53 with its 
negative regulator MDM2 (Kruse & Gu, 2009; Shangary & Wang, 2009) or by inhibiting 
MDM2 expression and E3 ligase activity as well as its intracellular localization (Lohrum et al, 
2000a; Tisato et al, 2017). This is based on the observation that MDM2 is often dysregulated 
in wild type p53 tumors by amplification or deletion of its negative regulator ARF (Wiman, 
2006). MDM2 amplification occurs in up to 4% in all tumors (Meric-Bernstam et al, 2019) and 
with even higher frequency in some specific cancer types. For example, around 20% of 
sarcomas and 15% of breast cancers overexpress MDM2 and/or MDMX (Burgess et al., 2016). 
The MDM2-p53 interaction site is located in the transactivation domain at the p53 N-terminus 
and in an N-terminal 106-amino acid long region on MDM2 (Chen et al, 1993; Picksley et al, 
 
Figure 7 Interaction of mutant p53 and the of redox homeostasis. Mutant p53 may exert dominant negative 
effects on wild type (wt) p53 thereby interfere with wt p53 redox regulations. Mutant p53 may also interact 
with master antioxidant regulator NRF2 which leads to aberrant regulation of ARE genes or genes of the 
proteosome machinery.  Furthermore, mutant p53 affects both angiogenesis and metabolic activities that can 
contribute to both antioxidant and prooxidant effects. Figure is from the review Eriksson, Ceder et al 2019. 
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1994). Crystal structures of MDM2’s N-terminal domain together with short peptides of p53 
(residues 15-29) have enabled detailed studies of this interaction. p53 forms a hydrophobic a-
helix, in which three residues Phe19, Trp23 and Leu26, insert into a deep pocket in MDM2. 
These three residues are also important for the transcriptional transactivation activity of p53 
(Kussie et al., 1996). p53 binds to a similar pocket in MDMX although the binding site in 
MDMX is shallower and more narrow (Popowicz et al, 2008).   
1.5.1.2 Nutlins and its derivatives 
The first small molecules to inhibit MDM2-p53 interaction were a series of cis-imidazoline 
analogues named Nutlins (Vassilev et al., 2004). In a nanomolar concentration range these 
compounds displaced recombinant p53 from MDM2, with Nutlin-3 displaying the most potent 
binding activity. Nutlin-3 and as well as many of the other MDM2 inhibitors mimic the helical 
p53 peptide by binding into the hydrophobic pocket in MDM2 (Shangary & Wang, 2009; 
Vassilev et al., 2004). Also other helix-binding proteins can be targeted by nutlins e.g. members 
of BCL-2 family, although to lower affinity (Shangary & Wang, 2009). Nutlins induce p53-
dependent cell cycle arrest or cell death in cancer cell lines, while normal cells only undergo 
transient growth arrest (Shangary & Wang, 2009; Wiman, 2006). RG7112, a Nutlin derivative, 
was the first MDM2 inhibitor to be tested in clinical trials (Tisato et al., 2017). A Phase I study 
in patients with MDM2-amplified liposarcoma demonstrated proof-of-concept effect with an 
increased p53 and p21 expression by immunohistochemistry compared to baseline (Ray-
Coquard et al, 2012) as was also seen in mRNA expression levels in circulating leukemic cells 
from AML and CLL patients (Andreeff et al, 2016). However, high doses were needed for 
clinical efficacy, and toxicity and several clinical adverse events related to the treatment were 
reported. Idasanutlin (RG7388), another Nutlin derivate, is a second generation MDM2 
inhibitor with even higher potency than RG7112 in vitro and in vivo (Ding et al, 2013; Tisato 
et al., 2017). A Phase I/Ib study showed tolerable safety (Montesinos et al, 2020) and analysis 
of leukemic blasts from the Idasanutlin-treated patients showed that MDM2 protein expression 
in leukemic blasts was correlated to clinical response (Reis et al, 2016). Idasanutlin was further 
tested in a Phase III clinical trial in AML patients (regardless of TP53 status) in combination 
with cytarabine (Montesinos et al., 2020; Tisato et al., 2017). The Phase III study had an 
integrated Phase II safety and efficacy criteria with a blinded interim analysis for futility 
(Montesinos et al., 2020). Unfortunately the study has been terminated for futility based on 
efficacy results (according to clinicaltrials.gov, NCT02545283).  
1.5.1.3 Other small molecules targeting p53-MDM2 interaction 
Besides Nutlin and Nutlin-derivatives, other classes of compounds have been identified that 
inhibit the p53-MDM2 interaction, such as benzodiazepines that have three benzene rings 
mimicking the three residues of p53, and spiro-oxindole compounds where the oxindole ring 
mimics the side chain of one of the residues in p53 (Trp23) and the spiro-pyrrolidine ring 
mimics the other two residues (Liu et al, 2019; Tisato et al., 2017). The spiro-oxide compound 
SAR405838 (MI-77303) also mimics the three residues while additional interactions are 
formed with the residues 10-18 of MDM2, achieving a high degree of binding. SAR405838 
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has completed two phase I clinical trials with acceptable safety profile (de Jonge et al, 2017; 
de Weger et al, 2019; Liu et al., 2019) and limited activity in patients with solid tumors out of 
which 89% had MDM2 amplifications (de Jonge et al., 2017). Most small molecules that target 
MDM2 work in similar way as Nutlins-3a i.e. they target the pocket of MDM2 and also bind 
its homolog MDMX, but with a lower affinity, (Liu et al., 2019) even though MDM2 and 
MDMX binding pockets are structurally similar (Shangary & Wang, 2009). There has also 
been interest in targeting the NoLS of ARF and MDM2 that localize the proteins to the 
nucleolus and thereby prevent p53 degradation by MDM2 (Lohrum et al., 2000a).    
Up until 2019, seven compounds targeting MDM2 have or are being evaluated in clinical trials. 
Idasanutlin has progressed the furthest and several compounds are in Phase I studies, including 
those mentioned above as well as AMG-232, APG-115 and HDM201 (Burgess et al., 2016; 
Liu et al., 2019). Although major efforts are being made, clinical efficacy has not fulfilled 
expectations and currently there is no p53-MDM2/MDMZ interacting inhibitor approved for 
clinical use.  
1.5.1.4 Stapled peptides targeting p53-MDM2/MDM4 interaction 
A different class of therapeutics are stapled peptides that mimic the p53 amino acid sequence 
bound by MDM2 and MDMX (Burgess et al., 2016). The peptides are generated by a chemical 
method called peptide stapling (Bernal et al, 2007; Brown et al, 2013) where introduction of 
hydrocarbon linkers between non-adjacent amino acids causes a turn of the a-helix resulting 
in better stability and affinity (Brown et al., 2013; Mortensen et al, 2019). Unmodified wild 
type p53 peptide is poorly taken up by cells (Bernal et al., 2007) and as the wild type p53 
peptide is an amino acid sequence that is also bound by other proteins, it has low affinity for 
MDM2 and MDM4 (Brown et al., 2013). Initial developed stabilized alpha-helix of p53 (SAH-
p53) peptides do not enter cells due to its negative charge at physiological pH. However, 
replacing certain amino acids to generate positively charged stapled peptide (SAH-p53-8) 
allowed active uptake by cells (Bernal et al., 2007). The uptake can further be improved by for 
example nanocarriers such as lipid bilayer disks (lipodiscs) as shown with EGFR-targeted 
lipodiscs loaded with VIP116 stapled peptide targeting p53-MDM2/MDM4 (Lundsten et al, 
2020). Thus, rational design of stapled peptides can generate stable products that are readily 
taken up by cells (Bernal et al., 2007; Brown et al., 2013) and tumor as shown by the 
radiolabeled 125I-PM2 stapled peptide (Spiegelberg et al, 2018). Treatment with PM2 improved 
median survival by 50% in mice carrying colorectal cancer xenografts harboring wild type p53, 
while treatment of mice with mutant TP53 or null tumor xenografts had negligible effect 
(Spiegelberg et al., 2018). There are many stapled peptides that are being tested preclinically 
and first to be tested in a clinical setting is ALRN-6924 (Burgess et al., 2016). ALRN-6924 
activates p53-dependent transcription with anti-leukemic effect in vitro and in vivo in mice 
(Carvajal et al, 2018). It was considered well tolerated in patients with solid tumors and 
lymphomas (Meric-Bernstam et al, 2017; Meric-Bernstam et al., 2019) and is being tested in 
several Phase I and II clinical trials in combination with chemotherapies or molecular targeted 
treatments in solid tumors and hematological malignancies (Burgess et al., 2016).   
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1.5.2 Reactivating mutant p53 
p53 is a tumor suppressor, and as discussed above (section 1.2.2), targeting tumor suppressors 
is challenging since the aim is to restore a normal function as opposed to inhibiting the 
oncogenic activity of an activated oncogene. In many cases, tumor suppressor proteins are not 
expressed in tumor cells, due to for example large deletions in tumor suppressor genes. 
However, p53 is unique among the tumor suppressor genes, considering its high frequency of 
missense mutation and high levels of expression in tumors (Soussi & Wiman, 2015). Also, 
missense mutant p53 protein can exert dominant negative effect on co-expressed wild type p53 
(Boettcher et al., 2019; de Vries et al., 2002; Hegi et al., 2000; Srivastava et al., 1993) and at 
least some missense p53 mutants have probably acquired GOF (Brosh & Rotter, 2009; 
Mantovani et al., 2019). The high expression of missense mutant p53 protein and the fact that 
the TP53 gene is by far the most frequently mutated gene in cancer, makes mutant p53 a highly 
attractive anti-cancer target (Bykov et al., 2018). Several studies have shown that restoration 
of wild type p53 in mice causes tumor regression (Martins et al, 2006; Ventura et al, 2007; Xue 
et al, 2007) and so if the abundant missense mutant p53 were to be reactivated to a wild type-
like protein it should elicit a robust anti-tumor response (Bykov et al., 2018). That the function 
of missense mutated p53 proteins can be restored has been demonstrated by studies introducing 
second-site suppressor mutations (described below) that add novel DNA contacts or increase 
the stability of the folded state of the core domain (Brachmann et al, 1998; Nikolova et al, 
2000; Wieczorek et al, 1996). Intensive efforts have been and are being made using rational 
drug design, molecular modelling and chemical library screening in order to identify 
compounds that target missense mutant p53, reactivate it and induce tumor suppression (Bykov 
et al., 2018). There are also preclinical efforts to target the 10% of TP53 mutations that are 
nonsense mutations (i.e. have premature stop codons), which result in non-functional truncated 
p53 protein (Bykov et al., 2018; Zhang et al, 2017).  
1.5.2.1 p53 protein structure  
The 393 amino acid-containing p53 protein contains several well defined domains: an amino-
terminal (N-terminal) transactivation domain (TA), a proline-rich (PR) SH3 ligand domain, 
central sequence specific DNA-binding core domain (DBD), a tetramerization domain and a 
carboxy (COOH)-terminal (C-terminal) regulatory region (Bullock & Fersht, 2001; Vousden 
& Lu, 2002). There are several regions in the p53 protein that are conserved across species, 
and four out of five of these regions are located in the DNA-binding core domain (Cho et al, 
1994). Nuclear-localization signals are located in the C-terminal region while nuclear export 
signals are located in both the N- and C-termini (Vousden & Lu, 2002). At least 36 residues 
are reported to be modified by for example phosphorylation, methylations, acetylation, 
ubiquitination, glycosylation, sumoylation, ADP-ribosylation and neddylation (Kruse & Gu, 
2009). Many of the DNA damage-induced phosphorylations occur at residues in the 
transactivation domain, for example S15 and S20 by ATM/ATR and Chk1/2, respectively. 
MDM2 and histone acetyltransferases CBP/p300 bind to the p53 N-terminus and ubiquitinate 
or acetylate sites in the C-terminus (Vousden & Lu, 2002). The C-terminal oligomerization 
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domain residues 312-365) mediate the formation of p53 tetramers that bind DNA containing 
four copies of consensus sequence (Cho et al., 1994; el-Deiry et al., 1992).  
Almost all TP53 missense mutations occur in the DNA-binding domain (Vousden & Lu, 2002). 
Thus, the first published crystal structure of p53’s DNA binding core domain (residues 102-
292) with a consensus DNA binding site in 1994 (Cho et al., 1994) provided good 
understanding of mutant p53 nature (Bullock & Fersht, 2001). The core domain consists of a 
b sandwich that serves as a scaffold for two large loops (L2 and L3 loop) and a loop-sheet-
helix (LSH) motif (L1, S2, S2´, S10, H2) (Cho et al., 1994). The b sandwich is a barrel-like 
structure of several b sheets. p53 contains a zinc atom that is tightly bound and important for 
the DNA binding activity. The zinc atom is coordinated by the two large loops: C176 and H179 
in the L2 loop and C238 and C242 in the L3 loop. DNA-p53 interaction involves three parts: 
1) LSH (H2 helix and L1 loop) contact with the major DNA groove 2) L3 loop contact with 
the minor DNA groove and, 3) phosphate contacts to the DNA backbone flanked by the major 
and minor groove contacts. Residues K120, C277 and R280 in the LSH make contact with the 
major DNA groove. R248 in the L3 loop contacts the minor DNA groove (Cho et al., 1994). 
Contact with the DNA backbone involves the phosphate groups on DNA and several residues 
including K120, S241, R248, R273, A276, R280, D281 and R283 (Cho et al., 1994; Wieczorek 
et al., 1996).  
The six hot spot mutants R175, G245, R248, R249, R273 and R282 (Bullock & Fersht, 2001; 
Freed-Pastor & Prives, 2012; Vousden & Lu, 2002) that account for almost a third of TP53 
mutations (Vousden & Lu, 2002) are all located in the DNA core domain (Cho et al., 1994). 
The two most frequently mutated of these R248 (9.6%) and R273 (8.8%) have direct contact 
with DNA (Cho et al., 1994). The other four mutants are critical for stabilizing p53 structure 
for example R175 which is close to the zinc binding site. R249 is adjacent to DNA binding 
R248 on the L3 loops and surrounded by parts of L2, L3, S3 of the  b sandwich. R282 on the 
H2 helix is important for LSH structure. G245 on the L3 loop is important for the L3 
confirmation to form contact between G245, C247 (in contact with zinc) and R249 (previous 
mentioned hot spot). Most mutations occur at residues that are closest to DNA i.e. L2 and L3 
loops and LSH as these locations will have the most detrimental effects on DNA binding.  
1.5.2.2 The concept: reactivation of DNA contact mutants  
As described (section 1.4.1.1), missense mutations of p53 can be divided into two types of 
mutations based on the wild type p53 crystal structure (Cho et al., 1994): DNA contact and 
structural mutations (Nikolova et al., 2000; Wieczorek et al., 1996). The arginines at position 
248 and 273 make contact with the DNA backbone (Cho et al., 1994) and so mutations of these 
sites result in loss of DNA binding while the native structure of the core domain is maintained. 
The residue T284 is located in the a-helix of p53’s DNA binding domain that lies in the DNA’s 
major groove. Substituting threonine (T) with arginine (R) allows contact with the DNA 
backbone due to the long basic side chain or arginine. Thus, introducing a second mutation at 
T284R of some DNA contact mutants (R273H, R273C and R248Q) resulted in novel protein-
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DNA backbone contacts and enhanced binding to DNA motifs in p53 downstream targets p21 
and GADD45 (Wieczorek et al., 1996). In the R273 mutant introduction of T284R restored 
transcriptional activity of a p53-responsive reporter plasmid to a comparable level of wild type 
p53 activity and inhibited proliferation of Saos-2 osteosarcoma cells. This indicates that 
mutations of some of the residues that bind the DNA backbone (i.e. S241, R282, R273 and 
R283 (Cho et al., 1994)) do not completely abolish sequence specific binding to p53 motifs in 
downstream target genes (e.g. p21 and GADD45) and may possibly be restored by 
pharmacological intervention (Wieczorek et al., 1996). Other residues that are in contact with 
DNA bases, such as K120, C277 and R280, seem more important for DNA binding specificity 
and such mutants are therefore presumably more difficult to restore.  
1.5.2.3 The concept: reactivation of structural mutants  
A major fraction of TP53 mutations affect the structural integrity and stability of the DNA 
binding domain of p53, so called structural mutants (Brachmann et al., 1998). These mutations 
result in destabilization of local confirmation or a global denaturation of the entire protein 
(Bullock et al, 2000).  Introduction of certain second-site suppressor mutation into structural 
mutants increased stabilization of parts of the core domain and restored p53 function 
(Brachmann et al., 1998; Nikolova et al., 2000). The second-site suppressor mutation N268D 
is located in the b-sandwich and mutation likely increases p53 core domain stability by forming 
new contacts between the two b-sandwich sheets. In contrast, the second-site suppressor 
mutations N239Y and S240N are both located in the L3 loop and form new interactions with 
the DNA backbone or b-sandwich sheet respectively. The individual second-site suppressor 
mutations did not induce global stabilization but local stabilizations were observed, suggesting 
that compounds targeting specific regions may have activity in specific tumorigenic mutations 
depending on the location of the mutation (Brachmann et al., 1998).  However, double second-
site mutations N268 and N239Y resulted in global stabilization and recovery of sequence 
specific DNA binding of tumor mutations G245S and V143A (Nikolova et al., 2000). G245S 
locates to the L3 loop of the DNA-binding region and is only weakly destabilized (Brachmann 
et al., 1998; Bullock & Fersht, 2001). V143A is an example of mutations located in the b-
sandwich sheet, a location that accounts for a quarter of all missense mutations, and leads to 
global denaturation of the protein (Bullock & Fersht, 2001). Thus, several structural p53 
mutants may be rescued by amino acid substitution elsewhere in the core domain, suggesting 
that small molecule-mediated rescue may be feasible. However, mutations affecting residues 
that coordinate the zinc atom i.e. C176 (L2 loop), H179 (H1 helix in the L2 loop) and C238 
and C242 (both L3 loop), will most likely be difficult to rescue as loss of zinc leads to structural 
collapse (Bullock & Fersht, 2001).  
1.5.2.4 Temperature sensitive mutants 
Many p53 mutants are temperature sensitive and retain native structure at lower temperatures 
while unfolded at 37°C (Friedlander et al, 1996; Kaar et al, 2010; Zhang et al, 1994). Hot spot 
mutant V143A has even stronger DNA binding and transcriptional abilities than wild type p53 
at 32.5°C. However, at 37°C it looses its structure as shown by undetectable staining with 
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monoclonal antibody PAb1620 that recognizes wild type p53 confirmation (Zhang et al., 
1994). The V143A, R175H, R248W, R249S and R273H mutants that are not able to bind DNA 
at 37°C can actually bind DNA at lower temperatures (25-33°C), and R273H, R248W and 
V143A activate transcription of the MDM2 promotor at 26°C. Heating the mutant proteins to 
37°C irreversibly abolished their DNA binding activity, although this destabilization could 
partly be rescued with the monoclonal anti-p53 antibody PAb1801. This illustrates that many 
hot spot mutants may have intrinsic capacity to bind DNA and can suggest that they potentially 
can be stabilized by small molecules (Friedlander et al., 1996).  
1.5.2.5 Cysteines - targets for electrophilic modifications 
Electrophiles are electron-deficient molecules that react with other molecules that have 
unshared valence electron pairs i.e. nucleophiles. A covalent bond is formed upon the donation 
of an unshared electron pair from a nucleophile to an electrophile (Eriksson et al., 2019; 
LoPachin et al, 2019). This type of reaction is important for many intracellular processes for 
instance enzyme activity and function (LoPachin et al., 2019). Intracellularly, deprotonated 
cysteines or selenocysteines are the strongest nucleophiles (Pace & Weerapana, 2013) and thus 
prime targets of electrophilic compounds (Eriksson et al., 2019). Although cysteine is the least 
abundant amino acid incorporated into proteins (2%) (Miseta & Csutora, 2000; Pace & 
Weerapana, 2013), its importance is reflected by the fact that it is one of the most frequently 
mutated amino acids associated with disease (Wu et al, 2007). The large atomic radius of the 
sulfur atom and the low dissociation energy of the S-H bond makes the thiol group of cysteines 
highly reactive. The thiol ionization state of the cysteine determines its nucleophilicity and 
reactivity, rendering it highly sensitive to quick (within minutes) changes in the protein 
environment. Besides reacting with electrophiles, cysteines may also bind metals, catalyze 
redox reactions and form disulfide bonds. Many of these processes are important for 
transcription factors and enzymes, such as kinases and protease, and thus many proteins have 
cysteines in sites important for catalytic activity, allosteric regulation or metal binding ligands 
(Pace & Weerapana, 2013).  
p53 has ten cysteines that are all located in the DNA binding core domain and are important 
for p53 structure. The cysteines have different thiol reactivity depending on their nucleophilic 
character and solvent accessibility. Thus, cysteines that are strong nucleophiles and exposed to 
the surface of the protein are the most reactive (Eriksson et al., 2019; Kaar et al., 2010) (Figure 
8). The wild type confirmation of p53 is important for its ability to bind DNA (Rainwater et al, 
1995) and due to cysteine’s importance in intracellular reactions it is not a surprise that redox 
modifications affects p53’s ability to bind DNA (Hainaut & Milner, 1993a; Hupp et al, 1993; 
Rainwater et al., 1995). Three cysteines (C176, C238 and C242) and H179 coordinate a zinc 
atom in the core domain (Bullock et al, 1997; Cho et al., 1994), rendering p53 DNA binding 
dependent on a reducing environment (Hainaut & Milner, 1993a). The zinc atom binds with 
high affinity to these cysteines which results in a stable structure  y bridging to the two loose 
L2 and L3 loops that bind DNA (Bykov et al, 2009; Cho et al., 1994). Thus, the zinc atom is 
crucial for proper folding of p53 (Bullock et al., 1997; Eriksson et al., 2019). Indeed, the hot 
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spot R175H mutation close to the zinc binding site is characterized by global denaturation 
(Bullock & Fersht, 2001; Bykov et al., 2009). Zinc is vital for the DNA binding ability of 
several other transcription factors, besides p53, e.g. NFkB (Hainaut & Milner, 1993a; Zabel et 
al, 1991). Furthermore, the zinc atom also protects the cysteines from oxidation, which would 
otherwise lead to disulfide-linked aggregation of p53 protein due to the formation of 
intramolecular or intermolecular disulfide bridges between p53 cysteines (Bykov et al., 2009). 
Oxidation of p53 could also lead to disulfide crosslinks with cysteines on other redox-sensitive 
proteins. For example, the R175H mutation, adjacent to C176 perturbs zinc coordination 
leading to an oxidation-prone mutant p53 protein. To summarize, both redox status and zinc 
bioavailability regulates p53 folding and activity (Bykov et al., 2009), which renders p53 
highly sensitive to electrophilic assaults (Eriksson et al., 2019) (Figure 8). 
1.5.2.6 Soft electrophiles 
Electrophilic (“electron lover”) compounds have atoms that are electron-deficient, thus 
partially positive, and react with nucleophilic (“nucleus lover”) groups that have unshared outer 
shell electron pairs (Fessenden et al, 1998). Many of the mutant p53-reactivating compounds 
identified so far share the property of targeting cysteines and are so called soft electrophiles 
(Bykov et al., 2018; Eriksson et al., 2019). Electrophiles can be divided based on their 
electronic disposition (softness or hardness) which determines the type of nucleophiles they 
will react with (LoPachin et al., 2019). The softness or hardness is determined by the ease of 
electrons to delocalize. A covalent bond is formed when the two atoms share outer-shell 
(valence) electrons, for example a single bond between two atoms is the sharing of one pair of 
electrons (Fessenden et al., 1998). As mentioned above, sulfur is a relatively large atom (Pace 
& Weerapana, 2013) and since the outer-shell electrons are far from the nucleus, electrons are 
easily distorted. This characterizes a so called soft nucleophile (LoPachin et al., 2019). Since 
electrophiles preferentially react with nucleophiles that are of comparable softness or hardness 
(LoPachin et al., 2019), soft electrophiles preferentially react with cysteines e.g. cysteines 
located in the core domain of p53(Bykov et al., 2018). Hard nucleophiles, such as the amino 
groups on lysine or histidine, are therefore not preferentially bound by soft electrophiles 
(LoPachin et al., 2019). For example the hard electrophilic group of cisplatin forms DNA 
adducts by binding to guanine residues which have hard nucleophilic groups. Besides the 
softness and hardness, also other factors, e.g. steric hindrance, will affect whether an 
electrophile reacts with a nucleophile (LoPachin et al., 2019). Importantly, any electrophilic 
compound that targets protein thiols would also be expected to induce oxidative stress, for 
example by conjugating to low molecular weight molecules such as the tripeptide glutathione 
in which thiol binding is less restricted by steric hindrance than thiol binding in larger proteins 
(Bauer et al, 2016; Bykov et al., 2018; Eriksson et al., 2019) (Figure 8). 
The first published mutant p53-reactivating compound was thiol binding CP-31398 (Foster et 
al, 1999). It was shown to stabilize wild type p53 binding and maintain active confirmation of 
newly synthesized mutant p53 (Foster et al., 1999; Rippin et al, 2002). Furthermore, CP-31398 
inhibited tumor growth of melanoma and colon carcinoma-derived xenografts (Foster et al., 
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1999) and progression of bladder cancer growth in a transgenic mouse model (Madka et al, 
2013). To date there are no ongoing clinical trials with CP-31398 (Bykov et al., 2018). 
The mutant p53-reactivating compound PRIMA-1 (p53 Reactivation and Induction of Massive 
Apoptosis) was identified by Bykov, Wiman and colleagues in a cellular screen of the US 
National Cancer Institute (NCI) Diversity set containing 2000 low molecular weight 
compounds with diversified structures (Bykov et al., 2002b). p53 null Saos-2 osteosarcoma 
cells containing exogenous tetracycline-regulated mutant p53 R273H (Tet-off) were treated 
with the library compounds to asses mutant p53-dependent growth suppression. PRIMA-1 
enhanced DNA binding of mutant p53, induced expression of p53 downstream targets such as 
p21, PUMA, BAX and MDM2 and exhibited mutant p53-dependent anti-tumor activity in vivo 
(Bykov et al., 2002b; Bykov et al., 2005b). PRIMA-1Met, now called APR-246 or 
Eprenetapopt, is a methylated form of PRIMA-1, and was shown to be more active than the 
original compound possibly due to increased lipophilicity and cell permeability (Bykov et al., 
2005b). APR-246 is the most clinically advanced mutant p53-targeting compound and results 
from phase Ib/II clinical trial in TP53 mutant MDS/AML have recently been published 
(Sallman et al., 2021). APR-246 is currently tested in a Phase III clinical trial in TP53 mutant 
MDS. Mechanism of action and clinical trials will be further discussed in section 1.5.3.  
STIMA-1 and MIRA-1 are two other soft electrophiles the preferentially target mutant p53 
expressing cells and induce p53 target genes (Bykov et al, 2005a; Zache et al, 2008a). MIRA-
1 was found in the same screen that identified PRIMA-1 as a mutant p53-reactivating 
compound (Bykov et al., 2009). Fersht and colleagues identified the Michael acceptor 3-
benzoylacrylic acid (3BA) and showed that it thermostabilizes the core domain of wild type 
p53 and several hot spot mutants (Kaar et al., 2010). 3BA increased the melting temperature 
of hot spot mutants R175H, Y220C, G245S, R249S and R282W by up to 3°C through covalent 
binding of cysteines. Derivatives of 3BA that lacked the a,b-unsaturated double bond, 
characteristic for a Michael acceptor, were not able to react with p53, demonstrating that the 
Michael addition reaction is essential for targeting wild type and mutant p53. Analysis by mass 
spectrometry (MS) showed that C124 and C141 were first to react (Figure 8), followed by 
C135, C182 and C277, and lastly C176 and C275.  
Fersht’s group also identified another class of thiol-reactive mutant p53 reactivating-
compounds that bind cysteines through nucleophilic aromatic substitution. These were 
electrophilic 2-sulfonylpyrimidines (SP) among which PK11007 showed anti-cancer activity 
both in a p53-dependent and independent manner (Bauer et al., 2016). PK11007 reactivated 
mutant p53 and stabilized wild type p53 by binding the surface exposed cysteines C277 and 
C182. PK11007 also induced oxidative stress by depleting glutathione, which had a more 
pronounced effect on mutant p53-harboring cells. 
Recently, a different type of compound, arsenic trioxide (ATO), has been shown to promote 
folded structure of several p53 mutants. Unlike the other molecules described, ATO does not 
contain carbons but has two cysteine-binding arsenic (As) atoms. Crystal structures of mutant 
p53 showed that the As atom covalently bound to a cryptic cysteine triad (C124, C135 and 
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C141) between the b sandwich and the LSH motif resulting in a confirmation shift of the 
cysteines, particularly C141. Specifically structural mutants were reactivated by ATO and 
increased in thermostability and capacity to bind p53 target genes PUMA and CDKN1A (p21). 
DNA binding p53 mutants were less affected by ATO. A cysteine triad can also be found in 
the oncogenic PML-RARa fusion protein in acute promyelocytic leukemia (APL) for which 
ATO is FDA-approved. ATO is being tested in phase I clinical trials in p53 mutated 
hematological diseases (Chen et al, 2020).  
1.5.2.7 Zn2+ chelating compounds 
As mentioned in section 1.5.2.5, the zinc atom in p53, coordinated by C176, H129, C238 and 
C242, is important for the structural integrity of the core domain (Bullock et al., 1997; Cho et 
al., 1994). Several studies have shown that manipulating zinc concentrations affects wild type 
p53 structure (Butler & Loh, 2003; Hainaut & Milner, 1993b; Meplan et al, 2000). This also 
has relevance for reactivation of mutant p53 (Bykov et al., 2018) (Figure 8). An analysis of the 
NCI database for substances that preferentially target mutants p53 (R175, R248 and R273) 
compared to wild type p53 identified the thiosemicarbazone zinc metallochaperone-1 (ZMC1 
[NSC319726]) (Yu et al, 2012). It is thought that ZMC1 is a synthetic metallochaperone by 
functioning as a Zn2+ ionophore i.e. a molecule that transports metal ions, in this case Zn2+ 
(Blanden et al, 2015; Loh, 2010; Yu et al, 2014). ZMC1 binds extracellular Zn2+ and diffuses 
it across the plasma membrane. TOV-112D ovarian cancer cells that harbor R175H mutant 
TP53 showed an increased Zn2+ concentration upon treatment with ZMC-1. R175H is a 
common “hot spot” TP53 mutation and due to the close proximity of the substituted residue to 
the zinc atom binding site, the R175H mutant is unable to bind zinc(Blanden et al., 2015). 
ZMC1 was found to restore the zinc binding capacity of the R175H mutant which reactivated 
its wild type p53 function (Blanden et al., 2015; Yu et al., 2014). ZMC-1 treatment also 
depletes glutathione, chelates iron and induces oxidative stress (Yu et al., 2012). However, in 
the presence of N-acetyl cysteine (NAC), ZMC-1 was still able to promote wild type 
confirmation and apoptosis in R175H harboring cells (Yu et al., 2014). 
COTI-2 is another thiosemicarbazone that has been reported to reactivate mutant p53 and have 
anti-tumor activity (Lindemann et al, 2019; Salim et al, 2016; Synnott et al, 2020). Its p53-
dependent mechanisms of action are not clear and it also has p53-independent effects, including 
inhibition of the PI3K-AKT pathway (Bykov et al., 2018). Nevertheless, it was shown to 
promote a folded structure of unfolded R175H mutant p53 to wild type confirmation as shown 
by PAb1620 staining in SKBR3 cells (Synnott et al., 2020). COTI-1 has been tested in Phase 






Figure 8 Mutant p53 rescue and induction of oxidative stress as mechanisms of cell death by mutant p53 
reactivating compounds. Mutant p53 reactivating compounds are electrophiles that target cysteines in mutant 
p53 which results in stabilization of its protein structure. Electrophiles also target nucleophiles such as 
cysteines (R-S-) in low molecular weight molecules (e.g. glutathione [GSH]) or proteins, or selenocysteine (R-
Se-) in selenoproteins (e.g. thioredoxin reductase 1 [TrxR1]) that are part of the antioxidant defense systems. 
Electrophiles induce oxidative stress contributing to its mechanism of action. Zinc chelation also reactivates 
mutant p53 and has effects on redox homeostasis. The crystal structure in the top of the figure shows the wild 
type p53 core domain (Cho et al, 1994) with cysteines colored according to their thiol reactivity (green most 
reactive, yellow least reactive) and the zinc atom in brown. Cysteines targeted by mutant p53 reactivating 
compounds have been indicated. MQ = methylene quinuclidinone, SP = sulfonylpyridines, 3BA = 3-




1.5.3.1 Mutant p53 reactivation 
Both prodrugs PRIMA-1 and APR-246 (Eprenetapopt/PRIMA-1Met) are spontaneously 
converted to the active product methylene quinuclidinone (MQ) (Lambert et al., 2009) (Figure 
9). Of note, this also generates formaldehyde which does not seem to contribute to the growth 
suppression, as shown by treating cells with up to 50µM formaldehyde. MQ is a Michael 
acceptor due to its chemically active double bond which is prone to participate in reaction of 
nucleophilic addition (described in 1.5.3.5). PRIMA-D (APR-320), an analog of PRIMA-1 that 
cannot be converted to MQ, or MQ-H (lacks Michael acceptor activity) are completely inactive 
(Lambert et al., 2009; Mohell et al., 2015; Zhang et al, 2018b). In cells, the most common 
nucleophilic targets will be thiol (-SH) groups, which are often found in proteins, for example 
p53 (Cho et al., 1994), but the most predominant cellular thiol is found in the antioxidant 
glutathione which is present at millimolar concentration in cells (Berg et al, 2007). The 
covalent binding of MQ to the mutant p53 core domain promotes wild type p53 conformation 
and apoptosis (Lambert et al., 2009). PRIMA-1 and APR-246 have demonstrated anti-cancer 
efficacy in several cancer types in vitro in cultured cells, in vivo in tumor xenograft mouse 
models as well as ex vivo in primary cultures and patient-derived organoids (Bykov et al., 
2002b; Ceder et al., 2020; Demir et al., 2020; Liu et al., 2015; Synnott et al., 2017; Zache et 
al, 2008b; Zandi et al, 2011) while their growth-inhibitory effect is less pronounced in non-
cancerous fibroblasts (Ceder et al., 2020; Hang et al., 2018; Mlakar et al, 2019) or keratinocytes 
(Mlakar et al., 2019).  
APR-246/MQ fulfills several criteria for a mutant p53 reactivating compound suggested by 
Fersht and colleagues. These include that the compound should bind and thermostabilize 
mutant p53, restore wild type p53 confirmation, induce p53 dependent transactivation of target 
genes and show p53-dependent synergy with MDM2 inhibitors that induce wild type p53 (Liu 
et al, 2013). MQ binding to wild type and mutant p53 has been demonstrated by mass 
spectrometry in Project II but also previously (Lambert et al., 2009; Zhang et al., 2018b). 
Thermostabilization has been observed using differential scanning fluorimetry (DSF, 
[measures protein melting temperature]) and circular dichroism spectroscopy (CD, [assesses 
a-helix and b-sheet structure]) of MQ-treated wild type and mutant (R273H and R175H) p53 
recombinant core domains (Zhang et al., 2018b). This study identified C277, which is the most 
reactive cysteine in p53 and located on the DNA binding surface (Cho et al., 1994; Kaar et al., 
2010), to be essential for MQ-mediated thermostabilization (Zhang et al., 2018b) in line with 
the findings in Project II. Also C124, that lies in the center of the flexible L1/S3 pocket (Cho 
et al., 1994), was targeted by MQ (Zhang et al., 2018b). R175H mutant p53 with Cys to Ala 
replacements at C124 and C277 could not be reactivated by APR-246, to induce cell death and 
activation of downstream targets in transiently transfected H1299 lung adenocarcinoma cells 




PRIMA-1/APR-246 also promote wild type p53 confirmation as shown by positive wild type-
confirmation specific PAb1620 antibody immunostaining (Bykov et al., 2002b; Liang et al, 
2011; Zhang et al., 2018b) and immunoprecipitation (Demir et al., 2020) as well as loss of 
immunostaining using the antibody PAb240 (Bykov et al., 2002b; Liang et al., 2011) or HO3.5 
(Zhang et al., 2018b) binding to epitopes exposed in mutated p53. PRIMA-1/APR-246 induced 
expression of p53 targets such as p21 (Bykov et al., 2002b; Demir et al., 2020; Liu et al., 2015). 
Preferential growth suppression in mutant p53 cells have been shown in various cell systems 
including isogenic cell lines and upon p53 knockdown (Ali et al., 2011; Bykov et al., 2002b; 
Bykov et al., 2005b; Ceder et al., 2020; Demir et al., 2020; Liu et al., 2015; Roh et al., 2011; 
Shi et al, 2008). Furthermore, synergistic effects have been reported upon combination 
treatment with PRIMA-1 and Nutlin-3 in pancreatic cancer cells harboring mutant TP53 (Izetti 
et al., 2014). Synergy with APR-246 has also been observed with Nutlin-3, Idasanutlin and 
MI-773 (SAR405838) in mutant TP53-carrying ovarian cancer cells (Ceder et al, unpublished 
data).  
1.5.3.2 Redox effects 
Apart from reactivating mutant p53, PRIMA-1/APR-246 can also disrupt redox homeostasis 
due to the electrophilic properties of MQ, contributing to PRIMA-1/APR-246-induced cancer 
cell death (Ceder et al., 2020; Haffo et al, 2018; Liu et al., 2017; Mlakar et al., 2019; Peng et 
al, 2013; Synnott et al, 2018; Tessoulin et al., 2014)  
 
Figure 9 APR-246 (Eprenetapopt) and PRIMA-1 form active product MQ. APR-246 (PRIMA-
1Met/Eprenetapopt) and PRIMA-1 both convert to active product methylene quinuclidinone (MQ) (Lambert 
et al, 2009). MQ is an Michael acceptor, a soft electrophile with an a,b-unsaturated bond (red) that is prone to 
nucleophilic addition with a Michael donor for example low molecular weight (LMW) thiols e.g. glutathione 
(GSH) or a thiol group (R-SH) in proteins e.g. p53. Another example of Michael donors are selenocysteine 
(Se)-containing proteins e.g. thioredoxin reductase 1 (TrxR1). MQ covalently conjugates to cysteine or 
selenocysteine in a Michael addition. The MQ binding is reversible (Ceder et al, 2020) and may undergo retro-
Michael addition, resulting in MQ travelling between thiols. 
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Glutathione is a low molecular weight molecule consisting of just three amino acids: γ-
glutamate, cysteine and glycine, and is highly abundant inside cells (Berg et al., 2007). 
Compared to thiols in protein, the thiol in glutathione is less sterically hindered and therefore 
readily conjugated by MQ (Lambert et al., 2009). Cells are highly adaptable to counteract 
oxidative stress through various mechanisms (section 1.6). However, any treatment with APR-
246 is accompanied by glutathione depletion and oxidative stress, which may contribute to cell 
death. Since also the function of wild type p53 is dependent on a reduced environment (Hainaut 
& Milner, 1993a), and since all activities are due to the reactivity of MQ it becomes difficult 
to separate the oxidative stress-induced mechanisms from the mutant p53-reactivating 
mechanisms. One of the building blocks, cysteine, is imported by xCT in its oxidized form 
(cystine). Both high expression of xCT and high glutathione levels are correlated with 
decreased sensitivity to APR-246 (Ceder et al., 2020; Liu et al., 2017). Also, inhibition of 
glutathione production by for example buthionine sulfoximide (BSO) drastically sensitizes 
cells to APR-246 (Lambert et al., 2009; Tessoulin et al., 2019; Tessoulin et al., 2014). 
Glutathione-conjugated MQ (GS-MQ) is exported via the multidrug resistance protein 1 
(MRP1) and upon inhibition leads to pronounced synergy with APR-246 as described in 
Project I (Ceder et al., 2020). Thus, APR-246 sensitivity is dependent on mutant p53, cellular 
thiol status as well as drug accumulation, but neither factor alone can fully explain the 
sensitivity to APR-246 . 
Glutathione is intracellularly highly abundant and nucleophilic due to its cysteine, however, 
the most potent cellular nucleophile is selenocysteine (Sec or U) (Ralston, 2018). 
Selenocysteine is a structural analogue of cysteine but with a selenium (Se) instead of the sulfur 
atom (Arner, 2010). Out of the 25 selenoprotein genes in human, around half are enzymes 
(Ralston, 2018). Thioredoxin reductase 1 (TrxR1) is one such enzyme and uses NADPH for 
the reduction of oxidized thioredoxin (Trx) and other substrates. Both TrxR1 and Trx are 
important for redox regulation (Arner, 2009). TrxR1 forms a homodimer with another TrxR1 
protein subunit. The selenium located in the selenylsulfide-motif (-GCUC-) at the C-terminal 
active site is reduced by the transfer of two electron from NADPH by the dithiol in the N-
terminal site (of the other TrxR1 subunit) and further transferred to the substrate (e.g. oxidized 
Trx). Thus, both subunits are required for its normal function (Arner, 2009). APR-246 targets 
the selenocysteine in TrxR1, resulting in inhibition of TrxR1 activity which decreases the 
antioxidant defense capacity of cells (Peng et al., 2013). In addition, modification of the 
selenocysteine residue by MQ converts TrxR1 to a dedicated NADPH oxidase (Peng et al., 
2013), as has previously been seen with other compounds that modulate TrxR1’s 
selenocysteine (Anestal & Arner, 2003; Anestal et al, 2008). Cisplatin inactivates TrxR1 in a 
similar way, and it has been proposed that this mechanism is important for its anti-tumor 
activity. Thus, APR-246 treatment does not just interrupt the antioxidant capacities of TrxR1, 
it also converts it to a NADPH oxidase with prooxidant properties which results in elevated 
oxidative stress contributing to APR-246-mediated cell death (Peng et al., 2013). Furthermore, 
MQ also inhibits Trx and glutaredoxin (Grx) which both are important antioxidants for 
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maintaining redox homeostasis, probably contributing to the oxidative stress observed in cells 
treated with APR-246 (Haffo et al., 2018). 
1.5.3.3 Mutant p63 and p73 reactivation 
p63 and p73, the other two members of the p53 family, share extensive sequence homology 
with p53, especially within the DNA binding domain. Therefore, it is not surprising that mutant 
versions of p63 and p73 could be reactivated by APR-246, as shown by upregulation of 
downstream targets p21 and Noxa (Rokaeus et al, 2010). p63 is important for regulating skin 
development and mice that have deleted p63 lack stratified epithelia in several organs (Barbieri 
& Pietenpol, 2006; Senoo et al, 2007). Mutation of p63 is associated with several rare disorders, 
including the ectodermal dysplasia syndrome (ED) (Aberdam et al, 2020; Rinne et al, 2007). 
ED results in abnormal development of tissues (e.g. skin, hair, teeth, nails and exocrine glands) 
that develop from the embryonal ectoderm (outer) layer (Rinne et al., 2007). Two major 
phenotypes are presented in ED patients: ectrodactyly, ectodermal dysplasia, and cleft 
lip/palate (EEC) and 1/ankyloblepharon-ectodermal dysplasia-clefting syndrome (AEC) 
(Aberdam et al., 2020). Besides the abnormal development of tissues around 40% of EEC 
patients also have clefts lips. AEC patients may be born with eyelids fusion (ankyloblepharon) 
and typically have extreme dry skin and sometimes patches that erode and do not heal . EEC 
syndrome is mainly caused by point mutations in the DNA binding domain while AEC 
syndrome-associated mutations occur in the C-terminal steril a-motif (SAM) domain (Rinne 
et al., 2007). There is no curative treatment for AEC and EEC patients (Aberdam et al., 2020). 
APR-246 rescued the mutant p63-associated phenotype of primary skin keratinocytes derived 
from EEC (Shen et al, 2013) and AEC syndrome patients (Aberdam et al., 2020). Fibroblasts 
from EEC patients that were reprogrammed to induced pluripotent stem cell (iPSC) lines and 
had impaired ability to differentiate into epidermal and corneal epithelial cells were rescued by 
APR-246. Treatment with APR-246 reverted the lineage commitment and restored normal p63 
signaling (Shalom-Feuerstein et al, 2013). Moreover, APR-246 was reformulated in a cream 
and applied topically on the eroded skin of two AEC patients (hand and scalp) (Aberdam et al., 
2020). In both patients the area treated with the cream showed re-epithelization of the eroded 
skin and decreased pain. These data suggest that APR-246 may be used for the treatment of 
local AEC erosions to decrease pain, leading to increased quality of life for these patients.  
1.5.3.4 Synergies with other compounds 
Combination treatment of APR-246 with several chemotherapeutic drugs and other targeted 
treatments have been reported to result in synergistic cell death or growth suppression (Bykov 
et al, 2016). There may be several reasons for why a combination treatment with APR-246 
leads to a synergistic anti-tumor outcome (Bykov et al., 2018). Mutant p53 reactivation to a 
wild type p53-like protein might increase sensitivity to DNA-damaging chemotherapeutic 
drugs that trigger the p53 activation cascade. Indeed, several studies have shown that cisplatin 
synergizes with APR-246 in inducing cancer cell death (Bykov et al., 2005b; Fransson et al., 
2016; Kobayashi et al., 2013; Liu et al., 2015; Mohell et al., 2015; Roh et al., 2011). The 
observed synergy may also be due to that cells are inactivating cisplatin by glutathione 
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conjugation followed by efflux of the conjugate (Ghosh, 2019; Ishikawa et al, 1994). 
Therefore, depletion of glutathione by MQ will most likely inhibit cisplatin export (Bykov et 
al., 2018). Synergy between APR-246 and compounds may also occur due to the compromised 
antioxidant capacity and increased oxidative stress induction attributed to APR-246 (section 
1.5.3.2) (Bykov et al., 2016). For example, cisplatin also induces oxidative stress, shown by 
increase in reactive oxygen species (ROS) such as hydroxyl radicals (Brozovic et al, 2010), 
which may sensitize the cells to the redox effects of MQ. Other chemotherapeutic agents having 
shown synergistic growth suppression or cell death in combination with APR-246 are listed in 
Table 2. Some of these combinations are being explored in the clinical trials including the 
combination with 5-azacitidine in TP53 mutant MDS patients (Sallman et al., 2021) (section 
1.5.3.7).  
The finding that mutant p53 binds master antioxidant regulator NRF2 (Lisek et al., 2018; Liu 
et al., 2017; Walerych et al., 2016) described in section 1.4.2.4 suggests interesting possible 
combination treatments with APR-246. Several proteosome inhibitors are currently used in the 
clinic for the treatment of multiple myeloma and mantle cell lymphoma (Sherman & Li, 2020). 
Bortezomib was the first to obtain FDA approval (2003) as a third of relapsed, refractory 
multiple myeloma patients responded to the treatment in Phase II clinical trials (Fricker, 2020). 
Bortezomib has recently become frontline treatment for multiple myeloma (Sherman & Li, 
2020). Carfilzomib and ixazomib were FDA-approved 2012 and 2015, respectively. It is 
thought that proteosome inhibitors are effective in hematological tumors due to the high 
secretory load making these cells dependent on proteostasis mechanisms (Sherman & Li, 
2020). Although these inhibitors are effective at inhibiting the proteosome, the downstream 
mechanisms that ultimately lead to cell death remain uncertain (Fricker, 2020). The proteosome 
machinery was identified as a major common target by mutant p53 via its interaction with 
NRF2 (Walerych et al., 2016) (Figure 7). In the presence of NRF2, mutant p53 binds to the 
promotors of proteosome genes (PSMA2 and PSMC1) and upregulates NRF2-dependent 
transcriptional activity which may be a resistance mechanism against proteosome inhibitors 
(Figure 7). This interaction was abolished upon treatment with PRIMA-1, and PRIMA-1 in 
combination with carfilzomib resulted in synergistic reduction of cell viability and proteosome 
activity in breast cancer cell lines. The combination treatment also resulted in synergistic tumor 
growth inhibition and significantly reduced frequency of lymph node and lung metastases in 
an orthotopic breast cancer xenograft model (Walerych et al., 2016).  
Mutant p53, through entrapment of NRF2, also negatively regulates transcription of the 
SLC7A11 gene, and hence production of the cystine/glutamate antiporter (Liu et al., 2017). The 
cystine/glutamate antiporter system xc- is made up of two subunits, xCT (SLC7A11) and 4F2 
(SLC3A2), and imports cystine (oxidized cysteine) while exporting glutamate (Lewerenz et al, 
2013). Cysteine is one of the key building blocks for the antioxidant glutathione (Lu, 2013) 
and a rate limiting substrate for glutathione synthesis (Lewerenz et al., 2013). Mutant p53 and 
NRF2 binding to the SLC7A11 promotor results in limited intracellular cysteine availability 
and therefore diminished glutathione synthesis, rendering mutant p53 harboring cells sensitive 
to oxidative stress (Liu et al., 2017). SLC7A11 expression was demonstrated to be a robust 
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predictive biomarker for APR-246 sensitivity. Furthermore, the combination of the xCT 
inhibitor sulfasalazine and APR-246 resulted in synergistic tumor suppression in esophageal 
cancer patient-derived xenografts and decreased GSH levels in the tumors (Liu et al., 2017). 
Later data suggests that the decreased glutathione levels led to increased retention of APR-
246’s active product MQ (Ceder et al., 2020). Glutathione-conjugated MQ (GS-MQ) is 
exported via efflux pump multidrug resistance protein 1 (MRP1). GS-MQ export can 
effectively be blocked by MRP1 inhibitors such as MK-571 and reversan, as well as by MRP1 
knockdown using siRNA (small interfering RNA), which were shown to result in pronounced 
synergistic growth suppression in vitro, in vivo and ex vivo (Ceder et al., 2020) (Project I). Both 
increasing drug accumulation and limiting the antioxidant capacity of cells are effective means 
to cause synergistic cell death in combination with APR-246. Synergy by limiting antioxidant 
capacity has also been demonstrated using glutathione synthesis inhibitor BSO (Lambert et al., 










s Alkylating agents Cisplatin, carboplatin 
(Bykov et al, 2005b; Fransson et al, 
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Anthracyclines Doxorubicin, daunorubicin 
(Ali et al, 2011; Demir et al, 2020; 
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(Ali et al., 2011; Liu et al., 2015; 
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p53-MDM2 inhibitor Nutlin-3 (Izetti et al, 2014) 
Radiation  (Krayem et al, 2019; Nikolaev et al, 2020; Supiot et al, 2008) 
xCT inhibitors Sulfasalazine, erastin (Ceder et al, 2020; Liu et al, 2017) 
MRP1 inhibitors MK-571, reversan (Ceder et al., 2020) 
GCL inhibitor BSO (Lambert et al, 2009; Tessoulin et al, 2019; Tessoulin et al, 2014) 
TrxR1 inhibitor Auranofin (Lisek et al, 2018) 
Proteosome inhibitor Carfilzomib (Walerych et al, 2016) 
BRAF inhibitor Vemurafenib (Krayem et al, 2016) 
BRAF inhibitor + 
radiation Vemurafenib (Krayem et al., 2019) 
MEK inhibitor Pimasertib (Najem et al, 2017) 
PI3K inhibitors BKM120, wortmannin, PHEN (Ali et al, 2016; Li et al, 2018) 
mTOR inhibitor Rapamycin (Ali et al., 2016) 
Histone methylation 
inhibitor DZNep (Cui et al, 2014) 
PARP inhibitors Olaparib, PHEN (Deben et al, 2016; Synnott et al., 2017; Yin et al, 2018) 
Prooxidant Piperlongumine (Hang et al, 2018) 
Table 2 Promising combination treatments with APR-246. The table summarize various types of 
compounds that have been published to lead to increased sensitivity or synergistic cell death / growth 
suppression in combination treatment with APR-246 or PRIMA-1. 5-FU = Fluorouracil, 5-Aza = 5-azacitidine, 
DZNep = 3-Deazaneplanocin A, PHEN = 6(5H)-phenanthridinone 
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2009; Tessoulin et al., 2019; Tessoulin et al., 2014) and TrxR1 inhibitor auranofin (Lisek et 
al., 2018). 
1.5.3.5 The active product MQ, a Michael acceptor  
A common feature of the mutant p53-reactivating compounds 
MQ (the active product of APR-246 and PRIMA-1), CP31398, 
MIRA-1, STIMA-1, 3-benzoylacrylic acid and KSS-9 is their 
electrophilic character and ability to perform Michael addition 
reactions. In other words, their chemical structures contain a 
carbon-carbon double bond ( C=C ) in close proximity to an 
electron withdrawing group (Bykov et al., 2009). An analysis of 
the NCI database comparing sensitivity of wild type p53 and 
mutant p53 expressing cells against various types of thiol-
reactive compounds (and a group of randomly selected 
compounds), showed that Michael acceptors were the most 
selectively active on mutant p53-expressing cells (Zhang et al, 
2018a). Thus, Michael addition reactivity seem to be important 
for mutant p53 reactivation.  
The carbonyl group in MQ i.e. the carbon atom connected by a 
double bond to an oxygen atom [ C=O ], is shown by purple 
shading in Figure 10. The oxygen (O) is more electronegative 
than carbon (C) which means that the bonding electrons are attracted towards oxygen 
(Fessenden et al., 1998). This results in a polar bond with an uneven distribution of electron 
density towards the oxygen, causing a negative partial charge (d-) at the oxygen and a positive 
partial charge (d+) at the carbon. A carbon-carbon double bond ( C=C ) (red shading in Figure 
10) conjugated to an electron-withdrawing carbonyl group is polarized, and therefore prone to 
nucleophilic attack at the partially positive (d+) carbon (Fessenden et al., 1998). Michael 
acceptors, such as MQ (Lambert et al., 2009), have an a,b-unsaturated C=C double bond 
coupled to an (electronegative) C=O group (Fessenden et al., 1998). Michael acceptors react 
with Michael donors (nucleophiles) in a Michael addition reaction forming a Michael adduct 
(Mather et al, 2006; Michael, 1887) (Figure 9).  
In the cellular environment Michael donors are largely represented by thiol groups found on 
highly abundant glutathione (GSH) or cysteines in proteins, for example in p53. As described, 
these cysteines are important for p53 function (Bykov et al., 2018). Selenocysteine, found for 
example in TrxR1, although much less abundant is much more reactive with Michael acceptors 
(Poole, 2015). MQ is a soft electrophile that preferentially reacts with soft nucleophiles such 
as thiols and selenols – in cysteine and selenocysteine, respectively (LoPachin et al., 2019; 
Ralston, 2018). Inside cells, MQ undergoes Michael additions forming a reversible adduct 
(Figure 9) on the partially positively charged b-carbon of MQ (as indicated in orange in Figure 
10) (Lambert et al., 2009). The Michael addition reaction rate with thiols is affected by pH (-
 
Figure 10 Michael acceptor 
MQ (APR-246’s active 
product). MQ has an a,b-
unsaturated double bond 
conjugated to an electron-
withdrawing carbonyl group 
which makes it polar and 
susceptible to nucleophilic 





log[H+], hydrogen/proton concentration) (Jackson et al, 2017; Mather et al., 2006). The thiol 
group (-SH) in cysteine is ionizable. Thus, at increasing pH (i.e. lower proton concentration) 
the thiol group is deprotonated, generating a thiolate anion (-S- [negatively charged ion]) which 
is much more reactive (Poole, 2015). The thiol Michael addition reaction rate increases with 
pH due to increased availability of the thiolate anion (Mather et al., 2006). Therefore, the 
reactivity of various cysteines with MQ is pH-dependent and also vary depending on the local 
environment affecting their pKa and hence the fraction deprotonated thiol (thiolate anion) at a 
given pH. 
The binding of MQ and thiols is reversible (Ceder et al., 2020) (Figure 9) which is discussed 
in Project I. This reversibility allows MQ to transfer between cellular thiol targets, for example 
between glutathione and p53, which presumably is an important feature of its mechanism of 
action. But the reversibility also makes the study of MQ-bound targets, such as those evaluated 
in Project III, difficult as MQ adducts may be lost or new MQ adducts may be formed during 
sample preparation. Since MQ’s reactivity derives from the electronegative oxygen, reducing 
the carbonyl group renders MQ inactive. A metal hydride reduction method, as for example 
sodium borohydride (NaBH4), is required to reduce the carbonyl group of a ketone (or 
aldehyde) while leaving a carbon-carbon double bond intact (Fessenden et al., 1998). 
Alternatively if there is an adduct at this bond, NaBH4 would prevent the reversible reaction, 
the retro-Michael addition. If MQ is bound to a p53 cysteine, as described in Project II, the 
MQ-thiol adduct becomes stable upon NaBH4 treatment. Therefore, reducing MQ enables the 
study of MQ-adducts by preventing any adducts from being lost, and new to be formed during 
sample preparation. This could be an important approach to study specific p53 cysteines bound 
by MQ, as described in project II, but would also enable pharmacodynamic studies (Abrahmsén 
& Hagberg personal communication) or the identification of novel MQ targets. 
1.5.3.6 Michael acceptors in clinical use 
Electrophilic functional groups and Michael acceptors have often been excluded or ignored in 
drug discovery programs due to their presumed indiscriminate reactivity (Barf & Kaptein, 
2012; Bauer, 2015; Jackson et al., 2017). MQ binding to thiol targets is reversible (Ceder et 
al., 2020) and reversible covalent inhibitors are considered to have lower risk of toxicities since 
levels of drug-protein adducts may not be sufficient to trigger an immune response (Bauer, 
2015). Furthermore, unlike the other mutant p53 reactivating compounds (Bykov et al., 2018), 
APR-246 is a prodrug and not instantly reactive, as the Michael acceptor MQ first needs to be 
formed (Lambert et al., 2009). These reasons could in part account for the benign safety profile 
described in APR-246-treated patients in the clinical trials (Ceder et al., 2020; Lehmann et al., 
2012)  
Nevertheless, several Michael acceptors have received FDA-approval for example afatanib, 
ibrutinib and osimertinib. These Michael acceptors undergo Michael addition with specific 
cysteines located in or close to the ATP-binding pockets of their protein targets (Barf & 
Kaptein, 2012; Jackson et al., 2017). Ibrutinib was FDA-approved 2013 for CLL and mantle 
cell lymphoma (MCL). It binds covalently to C481 close to the ATP-binding site of Bruton’s 
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tyrosine kinase (BTK) a key player in the B cell receptor (BCR) pathway and upregulated in 
CLL (Honigberg et al, 2010; Pan et al, 2007). This cysteine is conserved in nine other tyrosine 
kinases and indeed, ibrutinib also targets cysteines in for example EGFR (C797), HER2 (C805) 
and HER4 (C803) (Chen et al, 2016; Davids & Brown, 2014; Grabinski & Ewald, 2014).  
Activating mutations of epidermal growth factor receptor (EGFR) are major drivers in non-
small cell lung cancer (NSCLC) (Tsakonas & Ekman, 2018). The clinical efficacy of the first 
generation EGFR inhibitors was decreased due to a second-site mutation T790M which occurs 
in around 50-60% of the resistant cases of NSCLC (Engel et al, 2016; Thress et al, 2015). This 
fueled the development of second and third generation EGFR inhibitors and Michael acceptors 
afatinib and osimertinib that were approved for metastatic NSCLC harboring EGFR mutation 
in 2013 and 2015, respectively (Jackson et al., 2017). Both target C797 by Michael addition 
and osimertinib selectively targets this cysteine in the EGFR T790M mutant protein (Jackson 
et al., 2017) but may also show efficacy in patients without this mutation (Eide et al, 2020). 
The treatment-acquired EGFR mutation C797S substitutes the cysteine for the much less 
nucleophilic serine (Jackson et al., 2017) and is associated with osimertinib resistance (Thress 
et al., 2015). This demonstrates that thiol Michael addition reaction is important for the efficacy 
of these types of covalent inhibitors and that Michael acceptors that target thiols may indeed 
be very promising molecules for drug development and novel treatment strategies in patients.  
1.5.3.7 APR-246 in clinical trials 
The First-in-Human study of APR-246 in patients with hematological malignancies or prostate 
cancer concluded that APR-246 is safe with a favorable pharmacokinetic profile (Deneberg et 
al., 2016; Lehmann et al., 2012). APR-246 (Eprenetapopt) is currently being evaluated in 
several clinical trials in hematological malignancies and solid tumors as listed in Table 3. A 
phase III study is ongoing in TP53 mutant myelodysplastic syndrome (MDS) in combination 
with azacitidine. This combination was shown to be well-tolerated in a Phase Ib/II study with 
high rates of clinical response and molecular remission (Sallman et al., 2021). In 2020, Aprea 
Therapeutics received FDA Breakthrough Therapy Designation for APR-246 in the 
combination with azacitidine for the treatment of MDS with TP53 mutation. More recently, 
Aprea Therapeutics also received FDA Fast Track Designation for APR-246 in the treatment 









/Eprenetapopt  n*   
Estimated study 
completion and NCT 
identifier  
Phase III TP53 mutant MDS First line Azacitidine 154 Nov. 2020 
NCT03745716 




First line Azacitidine 53 May 2021 
NCT03588078 




First line Azacitidine 56 Jun. 2021 
Published data  
(Sallman et al, 2021) 
NCT03072043 




Azacitidine 31 Sep. 2021 
NCT03931291 





80 Dec. 2021 
NCT04214860 








Pembrolizumab 118 Jun. 2022 
NCT04383938 







116 Jun. 2023 
NCT04419389 


















Phase I Hematological 
neoplasms/Prostate 
carcinoma  
Refractory  36 Completed 
Published data 
(Deneberg et al, 2016; 
Lehmann et al, 2012) 
NCT00900614 




Dabrafenib 3 Terminated 
NCT03391050 




Cisplatin and  
5-FU 
38 Study suspended 
Pre-print available 
(Fujihara et al, 2020) 
NCT02999893 
Table 3 Clinical trials of mutant p53 reactivating APR-246 (Eprenetapopt) registered at ClinicalTrials.gov. 
Drug mechanisms: APR-246/Eprenetapopt: mutant p53 reactivation, Azacitidine: cytidine analog (interferes 
with DNA replication), Venetoclax: BCL2 antagonist, Pembrolizumab: anti-PD-1antibody, Ibrutinib: Bruton’s 
tyrosine kinase (BTK) inhibitor, Rituximab: anti-CD20 antibody, Cisplatin: DNA alkylating agent, 5-FU 
(Fluorouracil): fluorinated uracil analogue (interferes with DNA replication), Carboplatin: DNA alkylating agent, 
PLD (Pegylated Liposomal Doxorubicin Hydrochloride): DNA intercalating drug in a liposome-encapsulated 
form, Dabrafenib: B-Raf inhibitor. *Estimated patient enrollment or actual enrollment. 
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1.6 OXIDATIVE STRESS 
Oxidative stress may be viewed as an imbalance of when the oxidants outweigh the antioxidant 
capacity (Reuter et al, 2010). Exogenous sources resulting in oxidative stress include radiation 
or electrophilic compounds as described in earlier sections. But oxygen species may also be 
produced during endogenous processes e.g. oxidative phosphorylation in the mitochondria. 
Reactive oxygen species can cause DNA damage contributing to genomic instability 
(Holmstrom & Finkel, 2014). As described in section 1.3.1 DNA damage leads to wild type 
p53 stabilization and induction of for example growth suppression or apoptosis. Cells have an 
incorporated redox sensing system and NRF2 is considered as the master antioxidant regulator 
(Rojo de la Vega et al., 2018) (Figure 11). In a way, NRF2 is similar to p53: both are 
transcription factors that are kept at low levels during unstressed situations while stabilized in 
response to certain stress triggers. NRF2 is kept at low levels by an E3 ligase complex 
containing Kelch-ECH-associated protein 1 (KEAP1) which forms a dimer with NRF2 and 
ubiquitinates it, resulting in proteasomal degradation. KEAP1 has sensor cysteines (especially 
C151) that upon reacting with electrophiles and reactive oxygen species leads to a confirmation 
change so it that KEAP1 no longer ubiquitinates NRF2. Thus, upon oxidative stress newly 
synthesized NRF2 translocates to the nucleus where it can transactivate the over 200 genes 
 
Figure 11 Overview of redox homeostasis and indicated wild type p53 regulated pathways. Oxidative 
stress may be increased from exogenous and endogenous sources as indicated in the red box. This leads to 
oxidation of cysteines in Keap1 which thereby no longer ubiquitinates NRF2 for proteasomal degradation. 
Newly synthesized NRF2 can then transactivate ARE-containing genes which are part of the antioxidant 
defense system. The two major antioxidant systems are Trx and GSH. When Trx or GSH are oxidized they 
may be NADPH-dependently reduced by TrxR and GR, respectively. NADPH generating pathways are 
indicated in the grey box and may also be consumed by other pathways besides antioxidant defense systems. 
IDH = isocitrate dehydrogenases, ME = malic enzymes, G6PD = glucose-6-phosphate dehydrogenase, Prx = 
peroxiredoxins, Gpx = glutathione peroxidases, Grx = glutaredoxin, other abbreivations are mentioned in the 
text. Figure is from the review Eriksson, Ceder et al 2019. 
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containing antioxidant response elements (ARE). In cells, thiol-containing proteins and low 
molecular weight (LMW) thiols have important biochemical roles in maintaining the redox 
homeostasis as they can easily be oxidized and regenerated. Two such entity with antioxidant 
activity are glutathione (GSH) and thioredoxin (Forman & Dickinson, 2003). When Trx or 
GSH reduce oxidized thiols their oxidized forms may be NADPH-dependently reduced by 
TrxR or glutathione reductase (GR) respectively (Eriksson et al., 2019). Thus, NADPH is an 
important reductive power in cells and can be generated by the pentose phosphate pathway 
(PPP), a-ketoglutarate production or pyruvate metabolism. 
The role of oxidative stress in cancer is complicated. Oxidative stress may initiate cancer 
development and support proliferation, while oxidative stress can also cause cancer cell death 
(Hayes et al, 2020). Although antioxidants can protect against oxidative stress-induced DNA 
damage and therefore be cancer-preventive, they have a different effect once a tumor is already 
formed (Holmstrom & Finkel, 2014). Studies have shown that treatment with antioxidants in 
tumor carrying-mice accelerates tumor progression and increase metastasis (Le Gal et al, 2015; 
Sayin et al, 2014). Likewise, epidemiological studies that evaluated antioxidant supplements 
in cancer patients showed no effects or even accelerated cancer incidence (Alpha-Tocopherol, 
1994; Holmstrom & Finkel, 2014). Aberrant proliferation of cancer cells may generate 
oxidative stress. In order to cope with the increased oxidative burden cancer cells upregulate 
antioxidant systems and adapt their metabolic activity (Hayes et al., 2020; Holmstrom & 
Finkel, 2014). One way to increase antioxidant defense systems is upregulating NRF2 
activation which has been show to promote tumor growth, metastasis and therapy resistance 
(Rojo de la Vega et al., 2018). The “Warburg effect” refers to the increased use of aerobic 
glycolysis by cancer cells, which provides glucose for the NADPH-generating PPP. This gives 
cells reductive power to sustain their high need of antioxidants (Holmstrom & Finkel, 2014). 
Both reactive oxygen species and NRF2 have been shown to play roles in many or in all of the 
Hallmarks of Cancer (Rojo de la Vega et al., 2018; Trachootham et al, 2009). Considering the 
central role of redox imbalance in cancer and its important role in response to electrophilic 
compounds it has in this thesis been awarded its own Hallmark of cancer as marked in green 
in Figure 3. 
1.6.1 Glutathione 
As mentioned, the tripeptide glutathione is present at millimolar concentration (1-10mM) in 
mammalian cells (Berg et al., 2007; Cole, 2014b; Lu, 2013). Glutathione is synthesized de 
novo in the cytosol in a highly regulated process (Lu, 2013) (Figure 13). Cysteine (Cys) 
availability is a key determinant for glutathione synthesis(Lu, 2013). Cysteine is imported in 
its oxidized from, cystine (CySS), via the antiporter xCT (SLC7A11) (Lewerenz et al., 2013). 
Extracellularly, cysteine is readily autoxidized resulting in the formation of a disulfide bond 
between two cysteine molecules (CySS) (Lu, 2013). In addition, cysteine may be derived from 
methionine via the transulfuration pathway. The imported CySS is NADPH-dependently 
reduced by enzymes Trx and thioredoxin-related protein 14 (TRP14) (Eriksson et al., 2019) 
into two cysteine molecules which may be used for the synthesis of g-glutamylcysteine in an 
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ATP-dependent reaction catalyzed by rate limiting GCL (glutamate-cysteine ligase) (Lu, 
2013). GCL comprises of two subunits, GCL-catalytic subunit (GCLC) and GCL-modifier 
subunit (GCLM), on of which (GCLC) is negatively feedback-regulated by GSH (Seelig et al, 
1984). The last step of GSH synthesis in which glycine is added is catalyzed by glutathione 
synthetase (GS) (Lu, 2013). Besides being incorporated in glutathione, cysteine itself is also 
potent antioxidant .  
One of the most important roles of glutathione is to protect from oxidative damage by serving 
as a sulfhydryl buffer, for example by reacting with hydrogen peroxide and organic peroxides, 
harmful byproducts generated from aerobic metabolism. Glutathione cycles between a reduced 
thiol form (GSH) and an oxidized form (GSSG) where two tripeptides are connected by a 
disulfide bond. Glutathione reductase (GR) can reduce GSSG back to GSH using NADPH as 
the electron donor (Berg et al., 2007). The oxidized form makes up less than 1% (Forman & 
Dickinson, 2003) of the total glutathione pool. In other words, most cells have a ratio GSH to 
GSSG greater than 500 (Berg et al., 2007), as GSSG has deleterious prooxidant activities and 
often accumulate upon oxidative stress (Cole, 2014b). The GSH to GSSG ratio (GSH/GSSG) 
is an important determinant of the intracellular redox potential(Lu, 2013). Therefore, to 
maintain this ratio, GSSG will rapidly be reduced by GR (Forman & Dickinson, 2003), or 
exported through for example MRP1 (Cole, 2014b) upon oxidative stress and the accumulation 
of GSSG. When GSH and GSSG are released from cells, activities of g-glutamyltranspeptidase 
(GGT) and dipeptidase will lead to degradation of GSH to its building blocks that can be 
salvaged and used for GSH synthesis, thereby forming the g-glutamyl cycle (Lu, 2013). 
The millimolar concentration of glutathione reflects its many essential roles in the cell, not only 
in protecting from oxidative damage, but also in processes such as cell differentiation, 
proliferation and apoptosis (Cole, 2014b). Importantly, glutathione also plays a role in drug 
and free radical detoxification since it can conjugate to electrophilic compounds 
nonenzymatically or through the action of glutathione S-transferases (GST) (Forman & 
Dickinson, 2003). In cells, endogenous oxygen species are the major source of DNA damage 
and thus counteracting this oxidative damage is essential to prevent cancer, as DNA damage is 
a substantial contributor to chromosome instability and accumulation of mutations and 
deletions (Sablina et al., 2005).  
1.6.2 Efflux pump MRP1 
1.6.2.1 ABC-family 
ATP-binding cassette (ABC) transporters play a major role in exporting solutes across a 
membrane against a concentration gradient. Their evolutionary importance becomes evident as 
all eukaryotes, including bacteria and Achaea express these membrane proteins (Cole, 2014a). 
The ABC super family consists of 48 members divided into seven subfamilies (A-G). One of 
the major causes of multidrug resistance in cancer is failure of chemotherapy, and one of the 
primary reasons for this is overexpression are some of the members of the ABC-family. Not 
all members of the ABC family mediate drug resistance, but members from the ABC 
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subfamilies B, C and G contain known multidrug transporters (Bush & Li, 2002). The ABCB1 
(MDR1) was first described and is now known to transport a wide variety of molecules 
including drugs and dyes.  
1.6.2.2 Structure and function 
Multidrug resistance protein 1 (MRP1 or ABCC1) was discovered in 1992 and was the first 
identified member of the C subfamily. The ABCC1 gene was amplified at least 100-fold in the 
multidrug resistant lung cancer cell line from where the mRNA first was isolated (Cole et al, 
1992). MRP1 is a 190kDa protein and, unlike many of the other ABC proteins that contain a 
4-domain structure, MRP1 has a 5-domain structure, with three membrane-spanning domains 
(MSD) forming a pore which allows transportation powered by ATP hydrolysis at the two 
nucleotide-binding domains (NBD) (Cole, 2014a, b). Although MRP1 was identified in a 
multidrug resistant cancer cell line, it has several important physiological roles as it also exports 
endogenous substrates. Endogenous substrates can be exported either unconjugated such as 
folic acid, vitamin B12 or bilirubin, but also conjugated to either GSH (e.g. proinflammatory 
leukotriene C4), glucuronide (e.g. the steroid hormone 17β-estradiol) or sulfate (e.g. the steroid 
estrone 3-sulfate). MRP1 also exports byproducts from other processes that might be damaging 
such as the product and mediator of oxidative stress 4-hydroxy-2,3-trans-nonenal (4-HNE) 
generated from peroxidation of arachidonic acid in membrane phospholipids (Cole, 2014b). 
The relationship between glutathione and MRP1 is interesting, as some substrates need to be 
conjugated to GSH, while others are exported in the presence of GSH such as vincristine, 
etoposide and some anthracyclines. Some substances like Verapamil can even cause export of 
glutathione itself. Importantly, and as mentioned, GSSG, which can accumulate intracellularly 
upon oxidative stress can be exported through MRP1. Thus, MRP1 is a critical contributor to 
the thiol-redox homeostasis in cells (Ballatori et al, 2009; Bush & Li, 2002).  
1.6.2.3 Drug resistance 
Elevated MRP1 levels (mRNA and protein) can be found in most solid tumors and has been 
correlated with a negative clinical outcome as data indicate a role in drug resistance (Bush & 
Li, 2002). Due to its associated with drug resistance, targeting MRP1 could have therapeutic 
benefits. However, as MRP1 has important functions in normal cells as well, needs to be 
carefully modulated. Furthermore, MRP1 is found at pharmacologically sanctuary sites where 
it likely serves a protective role. For example, at the blood-testis barrier, MRP1 protects the 
testicular tubules against xenobiotic induced damage (Wijnholds et al, 1997; Wijnholds et al, 
1998). The quinolein derivative MK-571 is the most commonly used MRP1 inhibitor, but it 
can also inhibit other MRPs (Csandl et al, 2016), and was originally developed as a cysteinyl 
leukotriene receptor (CysLTR1) antagonist (Jones et al, 1989) for the purpose of treating 
asthma as it completely inhibits MRP1-mediated transport of leukotriene C4 (LTC4) (Cole, 
2014b; Li, 2006). Previous studies have combined MK-571 with chemotherapeutics, for 
instance with vincristine and demonstrated that MK-571 can revert resistance (Gekeler et al, 
1995). Interestingly, the MRP1/ABCC1 promoter contains p53 binding motifs (Bush & Li, 
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2002)  and studies show that while wild type p53 represses MRP1 (Wang & Beck, 1998), 
mutant p53 is associated with MRP1 accumulation (Sullivan et al, 2000).  
1.7 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 
A child is diagnosed with cancer almost every day in Sweden. Children rarely develop cancer 
and pediatric cancers are less than 1% of all cancer cases (Barncancerfonden, 2017b). One third 
of childhood tumors are leukemias, predominantly (90%) acute lymphoblastic leukemia (ALL) 
(Barncancerfonden, 2017a). Around half of the ALL cases occur in children and adolescents 
(Tran & Hunger, 2020) with the peak incidence at 2-5 years of age (Hein et al, 2020; Hunger 
& Mullighan, 2015). ALL arises in the bone marrow and are mainly of B cell precursor subtype 
or have T cell lineage (around 15%) (Hein et al., 2020), but subtype is also defined by 
differentiation status and genetics (Greaves, 2018). Symptoms of ALL include pallor, tiredness, 
pain in legs, bruises and wounds that do not disappear or heal, increased infection sensitivity 
and the continuous worsening of symptoms (Barncancerfonden, 2017a). Treatment of pediatric 
ALL has been a success story in oncology; from a deadly disease with survival rate below 10% 
in the 1960s to over 90% surviving patients today (Greaves, 2018; Hunger & Mullighan, 2015). 
Nonetheless, ALL remains the most frequent cause of death from cancer under the age of 20 
in the United States (Hunger & Mullighan, 2015). 
1.7.1 Genetic alterations in ALL 
Childhood ALL arises due to a combination of genetic predisposition or susceptibility at birth 
that results in a preleukemic state and secondary alterations that leads to ALL (Figure 12) (Hein 
et al., 2020; Zelent et al, 2004). Many of the chromosomal rearrangements in ALL (e.g. ETV6-
RUNX1, TCF3-PBX1, BCR-ABL) and hyperdiploidy (more than the usual diploid 
chromosomes) have been shown to occur in utero or prenatally and result in a preleukemic 
clone. A second alteration or factor is needed to trigger the transformation into ALL, which 
occurs  in a small fraction (0.2-1%) of these children (Ford et al, 1993; Hein et al., 2020). This 
also means that a large fraction of children that have the genetic predisposition and a 
preleukemic population actually never progress to clinical ALL (Greaves, 2018). For example, 
the ETV6-RUNX1 rearrangement occurs in 1-5% (Hein et al, 2019; Mori et al, 2002) of healthy 
newborns and the TCF3-PBX1 gene fusion in around 0.6% (Hein et al., 2019). These prenatal 
alterations are not sufficient for development of ALL and a second alteration is required to 
transform preleukemia to ALL. The frequency of ETV6-RUNX1 in healthy newborns is 100-
500-fold higher than the risk of developing leukemia supporting (Hein et al., 2020; Mori et al., 
2002), supporting the idea that secondary mutations are required for developing of ALL. This 
is also evident from the long latency of disease onset which may range between 1 to 15 years 
of age depending on which prenatal alteration is predominant (Hein et al., 2020; Hein et al., 
2019). It still remains unclear what causes the prenatal or initiating mutations and there is no 
pregnancy exposure associated with the genetic predisposition leading to preleukemia 
(Greaves, 2018). It is also unclear exactly how preleukemia develops into postnatal ALL, 
although the type of cell (e.g. stage of hemapoietic differentiation) where the genetic alteration 
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occurs in appears to be important. Infection or dysregulated immune response have been 
suggested to contribute to the leukemic transformation (Hein et al., 2020).  
ALL have distinct somatic genetic alterations such as changes in chromosome number 
(aneuploidy) or chromosomal rearrangements that can lead to deletion or gains in DNA 
sequences or result in the expression of a fusion protein. Chromosomal translocation results in 
the juxtaposition of an oncogene to a regulatory region of a gene that is actively transcribed, 
consequently leading to dysregulated and high transcription of the oncogene. Translocation 
may involve the juxtaposition of two genes in a manner that results in the expression of a 
chimeric fusion protein that has novel oncogenic functions (Hunger & Mullighan, 2015). The 
most common translocation in pediatric ALL (25%) results in the fusion of the two 
transcription factor genes ETV6 and RUNX1 (TEL-AML1) (Hein et al., 2020; Hunger & 
Mullighan, 2015). Fusion gene formation may also lead to constitutive activation of kinases 
such as c-Abl in BCR-ABL1 translocation (also known as the Philadelphia [Ph] chromosome) 
(Zelent et al., 2004). This is rare in childhood ALL (3%) but more common in adults (25%) 
(Hein et al., 2020). This translocation results in a protein distinctly expressed in the leukemic 
 
Figure 12 Timeline of childhood ALL development. Some mutations occur prenatally and results in a 
preleukemic clone which upon a secondary mutation may lead to development of ALL. TP53 mutations are 
rare in ALL but occur more frequently in relapsed patients. Inspired and modified from Hein et al, 2020 
licensed under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/ 
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cells and thus offers the possibility for therapeutic targeting. Twenty years ago, STI-571 
(Gleevec) became the first FDA-approved drug to specifically target an oncogenic protein 
(BCR-ABL) only expressed in cancer (Druker et al, 2001).  
1.7.1.1 TP53 mutations 
Although TP53 is the most frequently mutated gene in cancer, it is very rarely mutated in ALL 
with an incidence less than 5% at diagnosis (van Leeuwen, 2020). In ALL, genetic alterations 
involving tumor suppressors or cell cycle regulators are common, but for unknown reasons 
TP53 is spared (Comeaux & Mullighan, 2017). An exception is a rare subset of low 
hypodiploid B cell precursor ALL which is strongly associated with inherited TP53 mutations 
or the Li-Fraumeni syndrome (Greaves, 2018). Already 30 years ago, it was observed that 28% 
of the relapsed T-ALL patients, had acquired TP53 mutation which were absent at the first 
diagnosis (Hsiao et al, 1994). This observation has been confirmed in several studies, 
identifying mutations, deletion or 17p chromosomal aberrations in 10-30% of relapsed ALL 
cases (Blau et al., 1997; Comeaux & Mullighan, 2017; Diccianni et al., 1994; Gump et al., 
2001; Ma et al., 2015; van Leeuwen, 2020). Relapsed childhood ALL with TP53 mutation 




2 RESEARCH AIMS 
 
I. Investigate the role of MRP1 in APR-246/MQ drug export and redox balance for 
APR-246-mediated cancer cell death and how to target this mechansism for 
improved anti-cancer efficacy of APR-246.  
 
II. Determine the spectrum of cysteines in the p53 core domain targeted by APR-246’s 
active product MQ by locking its reversible binding. 
 
III. Explore ASNS as a putative target of APR-246 to improve asparaginase standard-
treatment-of-care for ALL. 
 
IV. Functionally characterize potential novel germline TP53 variants from Swedish 




3 RESULTS AND DISCUSSION 
3.1 PAPER I 
A thiol-bound reservoir enhances APR-246-induced mutant p53 tumor cell death 
The efflux pump MRP1 plays an important role in GSH-conjugated drug export but also in 
redox homeostasis by regulating the export of both GSH and GSSG (Cole, 2014a) (Figure 13). 
Since APR-246’s active product MQ is conjugated to GSH, and since MQ also induces 
oxidative stress (Lambert et al., 2009), we hypothesized that MRP1 may play a role in APR-
246-mediated cell death.  
Our analysis of data from the Cancer Dependency Map (DepMap) of 37 ovarian cancer cell 
lines identified MRP1 (ABCC1) mRNA as the gene whose expression showed the strongest 
correlation to PRIMA-1 resistance, in accordance with a previous analysis of the NCI database 
(Bykov et al, 2002a). Indeed, the combination treatment of APR-246 and MRP1 inhibitor MK-
571 resulted in synergistic growth suppression in 20 cancer cell lines and ex vivo in esophageal 
and colorectal cancer patient-derived organoids (PDO). Another MRP1 inhibitor, reversan, and 
MRP1 knockdown confirmed synergistic growth suppression, while overexpression of MRP1 
resulted in decreased APR-246 sensitivity. Using an esophageal cancer xenograft model in 
mice we showed that the combination treatment effectively suppressed tumor growth and 
increased survival. Inhibition of MRP1 with either of the two inhibitors or knockdown by 
siRNA resulted in increased 14C-content after 14C-APR-246 treatment. The increased 
intracellular level of 14C could be attributed to retention of GSH-conjugated MQ (GS-MQ), but 
 
Figure 13 Overview of MRP1’s and xCT’s role in GSH and Cys cycling and APR-246 mechanism. 
Antiporter xCT exports glutamate (Glu) and imports cystine (CySS [oxidized Cys]), CySS is reduced into 
cysteines (Cys) which can be used for glutathione production (GSH). GSH and oxidized GSH (GSSG) are 
exported by MRP1. Outside cells GSSG is reduced to GSH which is cleaved by peptidases to form Cys which 
is oxidized to CySS and can again be taken up by xCT. APR-246’s active product MQ can reversibly bind to 
GSH and Cys, as well as thiols in mutant p53 thereby reactivate p53 and induce cell death. The GSH-
conjugated MQ (GS-MQ) is exported by MRP1. Depletion of antioxidants GSH and Cys and accumulation of 
prooxidants GSSG and CySS lead to oxidative stress and contribute to cell death. Part of figure is from 
Eriksson, Ceder et al, 2019. 
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not prodrug APR-246, as demonstrated by mass spectrometry. Furthermore, we showed that 
GS-MQ binding is reversible since addition of N-acetylcysteine (NAC) resulted in NAC-MQ 
formation. Cells harboring mutant p53 are the most sensitive to single APR-246 treatment and 
exhibited the strongest synergy upon combination treatment with APR-246 and MK-571. 
Furthermore, high glutathione (GSH + GSSG) and low 14C-content after 14C-APR-246 
treatment correlated with low APR-246 sensitivity. However, neither mutant p53, thiol status 
nor drug accumulation alone could fully explain APR-246 sensitivity.  
Antiporter xCT imports cystine (CySS [oxidized cysteine]) and exports glutamate (Lewerenz 
et al., 2013). Upon import, CySS is reduced to cysteine (Cys) which may be used for GSH 
synthesis (Lu, 2013) (Figure 13). A previous study demonstrated pronounced synergistic 
growth suppression upon combination treatment with xCT inhibitors and APR-246 (Liu et al., 
2017). This was partly explained by the depletion of glutathione due to limited cystine/cysteine 
availability. Surprisingly, upon MRP1 inhibition with MK-571 we also detected a drop in total 
glutathione (GSH+GSSG) which was accompanied by increased expression of NRF2-
regulated xCT (Rojo de la Vega et al., 2018) and increased intracellular Cys and CySS 
concentrations. However, upon the combination treatment with APR-246, the MK-571-
induced Cys level dropped suggesting that intracellular Cys was consumed, modified or 
produced to a lower rate upon APR-246 treatment. We then compared the effect of MRP1 that 
limits drug export and xCT inhibition that limits cystine/cysteine availability. At concentrations 
of inhibitors that decreased total glutathione (GSH + GSSG) to similar extent, we saw an even 
more striking increase in intracellular 14C content upon 14C-APR-246 treatment in the xCT-
inhibited cells, compared to MRP1-inhibited cells. This suggests that cysteine/cystine 
availability is an important factor for MQ retention as well as APR-246-induced growth 
suppression.  
The retention of GS-MQ upon efflux pump MRP1 inhibition allows the formation of an 
intracellular active drug pool from which MQ may target thiols (or selenols) in other low 
molecular weight molecules or high molecular weight molecules such as p53. This active drug 
retention in combination with GSH depletion results in pronounced synergistic growth arrest 
upon the combination treatment with APR-246 and MRP1 inhibitor. Since reversible covalent 
inhibitors are considered to have lower risk of toxicities (Bauer, 2015), the reversible nature of 
MQ binding may not only be important for the efficacy, but also account for the benign safety 
profile observed in the clinical trials (Lehmann et al., 2012).   
The main findings of Project I are: 
• MRP1 inhibition increases GS-MQ retention in cells and shifts intracellular thiol status 
• GS-MQ binding is reversible and allows formation of an intracellular drug pool that 
can target other thiols for example in p53 
• MRP1 inhibtion results in pronounced synergistic growth suppression in vitro, in vivo 
and ex vivo.  
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3.2 PAPER II 
Spectrum of p53 cysteines targeted by APR-246 active product MQ 
The reversible binding of MQ complicates the study of MQ adducts, as adducts may be lost or 
new ones formed during sample preparation. For this reason we used the reducing agent NaBH4 
to reduce the ketone group of MQ, rendering MQ inactive or locked to the bound thiol. We 
analyzed MQ adducts on wild type p53 and R273H and R175H mutant recombinant p53 core 
domains (S94-K292). Samples were treated with APR-246’s active product MQ with or 
without NaBH4, trypsinized and then analyzed by mass spectrometry. Without NaBH4 
treatment, p53 cysteines were found to be modified at a frequency of <1.5% at MQ incubation 
concentrations up to 200 µM MQ but some up to 20-30% at 2 mM MQ. A much higher fraction 
of individual cysteines was found to be modified in samples treated with NaBH4, with some 
cysteines being almost completely MQ-conjugated after incubation at 100 µM MQ. 
The ten cysteines of p53 display different thiol reactivity based on chemical context and solvent 
accessibility in the folded protein (Kaar et al., 2010). Kaar et al. concluded that C182 and C277 
are the most solvent accessible cysteines in the p53 core domain. Previously, C277 has been 
identified as an MQ target by thermostability measurements and mass spectrometry (Zhang et 
al., 2018b). Also other mutant p53-reactivating compounds with Michael acceptor activity, i.e. 
3BA (Kaar et al., 2010) and PK11007 (Bauer et al., 2016) (described in 1.5.2.6), are known to 
target C182 and C277. The latter makes direct DNA contact (Cho et al., 1994) but despite 
PK11007 binding to this residue, p53 DNA binding was not compromised and transactivation 
of p53 targets was restored (Bauer et al., 2016). In agreement with these studies, we found that 
C182 and C277 are the most MQ-modified cysteines in wild type p53 and the two mutant 
proteins. Additionally, C229 was highly modified in all three recombinant proteins. 
Furthermore, Zhang et al. showed that C124 is important for mutant p53 reactivation by APR-
246 in R175H mutant p53-transfected cells (Zhang et al., 2018b). C124 is also targeted by the 
other two mutant p53-reactivating compounds (Bauer et al., 2016; Kaar et al., 2010). Indeed, 
we identified C124 as an MQ target in the mutants but only to a low extent in wild type protein. 
Similarly, C135 and C141 were modified to a greater extent in the mutants than in the wild 
type core domain. Mutation at R175H is structurally detrimental due to its proximity to the zinc 
atom coordinated by C176, H179, C238 and C242 (Cho et al., 1994), and thus the unfolding 
temperature (melting point) is significantly lowered. Therefore, one might expect that more 
cysteines are exposed in the R175H core domain also at room temperature (Bykov et al., 2018). 
However, we did not observe an overall higher degree of modification in the R175H mutant 
compared to the R273H mutant. 
The main findings of Project II are: 
• C182 and C277 in the p53 core domain are major targets of mutant p53 reactivating 
compound APR-246’s active product MQ 
• Reversible MQ adducts are locked upon NaBH4 reduction, enabling studies of the 
degree of modifcation of individual cysteines in p53.  
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3.3 PAPER III 
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing 
growth suppression in acute lymphoblastic leukemia cells 
Given the reactive and reversible nature of APR-246’s active product MQ adduct formation, it 
is likely that APR-246 targets additional proteins than what has been described. We applied 
mass spectrometry-based cellular thermal shift assay (MS-CETSA) to identify potential novel 
MQ targets. MS-CETSA identified asparagine synthetase (ASNS) as one of the most 
thermostabilized proteins upon MQ treatment. We validated thermostabilization of ASNS 
using Western blot-CETSA (WB-CETSA) in acute lymphoblastic leukemia (ALL) cells. 
Presence of mutant p53, low GSH level and low xCT level were factors that correlated with 
increased APR-246 sensitivity in solid tumors (Ceder et al., 2020; Liu et al., 2017), but seemed 
less relevant for APR-246 sensitivity in ALL cells. 
Although we did not see a correlation of mutant p53 and APR-246 sensitivity in our small panel 
of cell lines, mutant p53 reactivation and APR-246 efficacy have been demonstrated in ALL 
cells (Demir et al., 2020). TP53 mutation is rare in ALL but occurs at higher frequency in 
relapsed patients (van Leeuwen, 2020). For decades, asparaginase has been used for treatment 
of ALL, based on the finding that ALL cells are asparagine-auxotrophs (Lanvers-Kaminsky, 
2017). We confirmed the observation (Aslanian et al., 2001) that ASNS-expressing ALL cells 
are less sensitive to asparaginase treatment. Since ASNS was identified as a potential MQ 
target, we combined APR-246 and asparaginase treatment and observed synergy in several of 
the tested ALL cell lines. Eight out of the ten tested ALL cell lines exhibited synergistic growth 
suppression.  
The finding that APR-246’s active product MQ target ASNS creates a novel therapeutic option 
for ALL patients as APR-246 is currently being tested in Phase III clinical trials. Also other 
solid tumors that are sensitive to both asparaginase and APR-246 may benefit from this 
combination treatment. 
The main findings in Project III are: 
• ASNS is a putative target of APR-246’s active product MQ 
• Combination treatment with APR-246 and standard-treatment-of-care asparaginase 





3.4 PAPER IV 
Functional characterization of novel germline TP53 variants in Swedish families 
In a Swedish cohort of Li-Fraumeni syndrome (LFS) or hereditary breast cancer (HrBC) 
patients we identified 24 different TP53 variants. Ten of these had not been reported as 
germline mutations in the International Agency for Research on Cancer (IARC) nor in TCGA 
by the NIH. Of these ten we functionally characterized four frame-shift mutations, one deletion, 
one nonsense mutation and three missense mutations.  
We determined wild type p53 activity using an eGFP reporter system containing several p53 
consensus DNA-binding sites and expression of p53 targets e.g. MDM2 as assessed by Western 
blotting. We also evaluated the capacity of cells harboring the mutant variants to induce cleaved 
caspase 3 and cell death. None of the frameshift variants nor the deletion variant were able to 
induce GFP expression by binding the consensus sites or express p53 target MDM2. The 
nonsense mutant did show partial wild type p53 activity by GFP expression  and also induction 
of MDM2. This could be related to the fact that its premature stop codon is situated relatively 
close to the C-terminus. Induction of GFP expression by the F134L and R110C missense 
mutant was also partial, while the P190S missense mutant induced GFP expression to similar 
levels as wild type p53. P190S was later determined not to be a germline mutation but a somatic 
mutation in a woman with breast cancer and family history of breast cancer. The two missense 
mutants, R110C and P190S, were able induce expression of MDM2, indicating that they retain 
p53 transcriptional transactivation activity. Annexin V/p53 co-staining by flow cytometry 
revealed that none of the mutants induced Annexin V in p53-positive cells to the same degree 
as wild type p53 transfected cells, although Annexin V, as marker of cell death, was stained to 
some extent.  
As described in the previous section 1.4.1.1, a large number of mutations have been reported 
in the TP53 variant database (Leroy et al., 2017). Therefore it is of high importance to 
understand which mutations are pathogenic in order to offer genetic counselling to families 
with hereditary cancer and the presence of these mutations. In our functional assays, some of 
the mutants identified from LFS or HrBC families were found to be potentially pathogenic 
although to a varying degree.  
The major findings in Project IV are: 
• TP53 variants that have not previously been reported as germline mutations were 
identified in families with Li-Fraumeni syndrome or hereditary breast cancer. 
• Frameshift variants and a deletion variant completely lacked wild type p53 activity 




3.5 ETHICAL CONSIDERATIONS 
Project I includes experiments with material derived from colorectal or esophageal cancer 
patients. The patient-derived material was used for establishing patient-derived organoids 
(PDO) which were used for in vitro experiments. All experiments followed the principles in 
the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont 
Report as described in the Material and Methods section in the paper. All experiments 
involving PDOs were approved by the local ethical committees and all patients gave individual 
informed consent. This project also involved experiments in mice. All of these experiments 
were approved by the local ethical committee and are further described in the Material and 
Method section (Ceder et al., 2020).  
The TP53 mutants examined in Project IV are derived from patients, although no patient 
material was used in the study. All patient gave consent to participate in the clinical biobank 
used for diagnostic and technical development as described in the Material and Methods section 




4 CONCLUSIONS AND FUTURE PERSPECTIVES 
Most of the mutant p53 reactivating compounds, including APR-246’s active product MQ, 
have electrophilic properties (Bykov et al., 2018). Consequently, any study with these 
compounds also affects the redox environment in cells which subsequently affects mutant p53 
(section 1.5.2.5). In the opposite direction, mutant p53 also affects redox homeostasis (section 
1.4.2.4). In Project I we showed MQ adduct formation is reversible and in Project II we 
established a method involving a reducing agent to lock MQ adducts. Locking MQ to its bound 
thiol enables identification of novel targets but may also facilitate the use of MQ as a biomarker  
after APR-246 treatment. In Project I we also discovered that both intracellular GSH and Cys 
content determine APR-246 sensitivity. Both GSH and Cys content is regulated by antiporter 
xCT expression which has been identified as a predictive biomarker for APR-246 sensitivity 
(Liu et al., 2017). Both xCT and the potential MQ target ASNS (identified in Project III) are 
regulated via NRF2 and another transcription factor ATF4 (Chen et al, 2004; Ishii & Mann, 
2014). Mutant p53 interacts with NRF2 and affects its transactivation activities (Lisek et al., 
2018; Liu et al., 2017; Walerych et al., 2016). Thus, exploring the relationship between mutant 
p53, NRF2, xCT and ASNS would be highly interesting, especially since PRIMA-1 (APR-246 
analogue) treatment is shown to disrupt mutant p53-NRF2 interaction (Walerych et al., 2016). 
High activity of xCT may render tumor cells glutamine-dependent as glutamine is utilized for 
generating glutamate that is exported with the imported cystine (Koppula et al, 2020; 
Timmerman et al, 2013). Since asparaginase also has glutaminase activities (Parmentier et al., 
2015), APR-246-induced xCT upregulation (shown in Project I) may make ALL cells more 
sensitive to asparaginase. This would provide another explanation for the observed synergy in 
ALL cells, especially for those with low ASNS expression. Furthermore, tumor cells that 
express high levels of antiporter xCT have high NADPH consumption due to constant 
NADPH-dependent reduction of imported cystine. This renders these tumors dependent on the 
NADPH-generating phosphate pentose pathway (PPP) and glucose (Joly et al, 2020; Liu et al, 
2020). Hence, using inhibitors to target PPP or glucose uptake in combination with APR-246 
should be explored as combination treatments. Lastly, in Project IV we identified TP53 
germline mutations that have not been previously described. Due to the vast number of reported 
TP53 mutations (section 1.4.1.1) it is highly important to identify which mutations may be 
pathological and which not.    
In summary, the first three projects provide important new knowledge on the mechanisms for 
APR-246-induced cancer cell death. Our data establish a solid foundation for novel 
combination treatment strategies with APR-246, for example combination with compounds 
regulating redox homeostasis or metabolism. Furthermore, the projects also highlight the 
various roles of mutant p53 in response to treatment as well as its pathogenic role in families 
with hereditary cancer. Understanding both the drivers of tumor development and the players 
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